Skip to content
← Breast Cancer

TREATMENT READING

Breast Cancer, part 3

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

248 sections
  1. Hormone replacement therapy
  2. Surgical Treatment for Breast Cancer
  3. Surgical Staging of the Primary Tumor
  4. Axillary Lymph Node Management
  5. Breast Reconstruction
  6. Radiation Therapy for Breast Cancer
  7. Post–Breast-Conserving Surgery
  8. Omission of radiation therapy for favorable, early-stage breast cancer
  9. Partial breast irradiation
  10. Regional nodal irradiation
  11. Postmastectomy
  12. Timing of Postoperative Radiation Therapy
  13. Acute and Late Toxicities of Radiation Therapy
  14. Systemic Therapy for Stages I, II, and III Breast Cancer
  15. Patient Selection, Staging, Treatment, and Follow-Up
  16. Stages I, II, and III HER2-Negative Hormone Receptor–Positive Breast Cancer
  17. Preoperative endocrine therapy for HER2-negative hormone receptor–positive breast cancer
  18. Postoperative systemic therapy for HER2-negative hormone receptor–positive breast cancer
  19. Anthracycline-containing chemotherapy
  20. Non–anthracycline-containing regimens
  21. Timing of postoperative chemotherapy
  22. Endocrine therapy
  23. Tamoxifen
  24. Tamoxifen and chemotherapy
  25. Ovarian ablation, tamoxifen, and chemotherapy
  26. Aromatase inhibitors
  27. Premenopausal women
  28. Postmenopausal women
  29. Initial therapy
  30. Sequential tamoxifen and AI versus 5 years of tamoxifen
  31. Sequential tamoxifen and AI for 5 years versus an AI for 5 years
  32. One AI versus another for 5 years
  33. Switching to an AI after 5 years of tamoxifen
  34. Duration of AI therapy
  35. Endocrine therapy and cyclin-dependent kinase (CDK) inhibitor therapy
  36. Bone-Modifying Therapy for Stages I, II, and III Breast Cancer
  37. Adjuvant PARP Inhibitors for Patients with Germline BRCA1 and BRCA2 Variants
  38. Stages I, II, and III Triple-Negative Breast Cancer (TNBC)
  39. Preoperative therapy for TNBC
  40. Chemotherapy
  41. Immunotherapy
  42. Postoperative therapy for TNBC
  43. Capecitabine therapy
  44. Immunotherapy
  45. Stages I, II, and III HER2-Positive Breast Cancer
  46. Preoperative therapy for HER2-positive breast cancer
  47. Trastuzumab
  48. Pertuzumab
  49. Postoperative therapy for HER2-positive breast cancer
  50. Trastuzumab
  51. Pertuzumab
  52. Trastuzumab emtansine (T-DM1)
  53. Neratinib
  54. Node-negative, small, HER2-positive breast cancer
  55. Toxicity of Systemic Therapy
  56. Capecitabine and Fluorouracil Dosing
  57. Toxicity of Adjuvant Chemotherapy
  58. Cardiac Toxic Effects With Adjuvant Trastuzumab
  59. Cardiac Toxic Effects With Pertuzumab and Lapatinib
  60. Toxicity of Endocrine Therapy
  61. Treatment of Locoregional Recurrent Breast Cancer
  62. Treatment of Metastatic Breast Cancer
  63. Treatment Option Overview for Metastatic Breast Cancer
  64. Metastatic HER2-Negative Hormone Receptor–Positive Breast Cancer
  65. Endocrine therapy and cyclin-dependent kinase (CDK) inhibitor therapy
  66. First-line palbociclib and endocrine therapy
  67. First-line ribociclib and endocrine therapy
  68. First-line abemaciclib and endocrine therapy
  69. Second-line palbociclib and endocrine therapy
  70. Second-line ribociclib and endocrine therapy
  71. Second-line abemaciclib and endocrine therapy
  72. CDK inhibitor therapy after disease progression on a prior CDK inhibitor
  73. Single-agent CDK inhibitor therapy
  74. Mammalian target of rapamycin (mTOR) inhibitor therapy plus endocrine therapy
  75. AKT inhibitor therapy
  76. Capivasertib
  77. Alpelisib plus endocrine therapy
  78. Elacestrant
  79. HDAC inhibitor therapy
  80. Endocrine therapy alone
  81. Tamoxifen and AI therapy
  82. Fulvestrant
  83. First-line fulvestrant
  84. Second-line fulvestrant
  85. Combination endocrine therapy with an AI and fulvestrant
  86. Sequencing therapy for hormone receptor–positive metastatic breast cancer
  87. Poly (ADP-ribose) polymerase (PARP) inhibitor therapy
  88. Sacituzumab govitecan
  89. Chemotherapy
  90. Metastatic HER2-Low Breast Cancer
  91. Metastatic Triple-Negative Breast Cancer
  92. Chemotherapy plus immunotherapy
  93. Pembrolizumab
  94. Atezolizumab
  95. Sacituzumab govitecan
  96. PARP inhibitor therapy
  97. Chemotherapy
  98. Immunotherapy monotherapy
  99. Metastatic HER2-Positive Breast Cancer
  100. Monoclonal antibody therapy
  101. Trastuzumab
  102. Pertuzumab
  103. Trastuzumab emtansine
  104. Trastuzumab deruxtecan
  105. Margetuximab
  106. Tyrosine kinase inhibitor (TKI) therapy
  107. Tucatinib
  108. Neratinib
  109. Lapatinib
  110. mTOR inhibition
  111. Germline BRCA-Mutated Metastatic Breast Cancer
  112. Olaparib
  113. Talazoparib
  114. High Tumor Mutational Burden Breast Cancer
  115. Pembrolizumab
  116. Chemotherapy for Metastatic Breast Cancer
  117. Capecitabine and fluorouracil dosing
  118. Cardiac toxic effects with anthracyclines
  119. Surgical Treatment for Metastatic Breast Cancer
  120. Radiation Therapy for Metastatic Breast Cancer
  121. Bone-Modifying Therapy for Metastatic Breast Cancer
  122. Treatment of Ductal Carcinoma In Situ
  123. Introduction
  124. Treatment Options for DCIS
  125. Breast Cancer Treatment
  126. Join a Clinical Trial
  127. Local treatments
  128. Surgery for Breast Cancer
  129. Radiation for Breast Cancer
  130. Systemic treatments
  131. Chemotherapy for Breast Cancer
  132. Hormone Therapy for Breast Cancer
  133. Immunotherapy for Breast Cancer
  134. Targeted Therapy for Breast Cancer
  135. What kind of treatment will I receive?
  136. Breast Cancer Treatment by Stage
  137. Breast Cancer During Pregnancy
  138. Ductal Carcinoma in Situ (DCIS)
  139. Inflammatory Breast Cancer Treatment
  140. Triple-Negative Breast Cancer Treatment
  141. Paget Disease of the Breast
  142. Breast Cancer Treatment by Stage
  143. Treatment of stage 0 breast cancer (ductal carcinoma in situ)
  144. Treatment of stages I to III breast cancer
  145. Treatment of locoregional recurrent breast cancer
  146. Treatment of stage IV (metastatic) breast cancer
  147. Chemotherapy for Breast Cancer
  148. Who gets chemotherapy for breast cancer?
  149. When is chemotherapy for breast cancer given?
  150. Chemotherapy after surgery for breast cancer
  151. Chemotherapy before surgery for breast cancer
  152. Chemotherapy drugs used for breast cancer
  153. Side effects of chemotherapy
  154. Hormone Therapy for Breast Cancer
  155. Who gets hormone therapy?
  156. What types of hormone therapy are used for breast cancer?
  157. Therapies that block ovarian function (ovarian ablation)
  158. Aromatase inhibitors to block estrogen production
  159. Therapies that block estrogen’s effects
  160. How is hormone therapy used to treat breast cancer?
  161. Adjuvant therapy for early-stage breast cancer
  162. Neoadjuvant therapy for breast cancer
  163. Treatment of advanced, metastatic, or recurrent breast cancer
  164. What are the side effects of hormone therapy?
  165. What if side effects of hormone therapy interfere with my life?
  166. How effective is hormone therapy?
  167. Can other drugs interfere with hormone therapy?
  168. Immunotherapy for Breast Cancer
  169. Who gets immunotherapy for breast cancer?
  170. When is immunotherapy for breast cancer given?
  171. Immunotherapy drugs used for breast cancer
  172. Side effects of immunotherapy
  173. Inflammatory Breast Cancer Treatment
  174. Treating stage III (also called stage 3) inflammatory breast cancer
  175. Treating metastatic or stage IV (also called stage 4) inflammatory breast cancer
  176. Treatment for recurrent inflammatory breast cancer
  177. Clinical trials
  178. Coping with inflammatory breast cancer treatment
  179. Radiation for Breast Cancer
  180. Types of radiation therapy for breast cancer
  181. External beam radiation therapy for breast cancer
  182. Whole breast radiation therapy
  183. Partial breast external beam radiation therapy
  184. Intraoperative radiation therapy
  185. Brachytherapy for breast cancer
  186. Intracavitary brachytherapy
  187. Interstitial brachytherapy
  188. Permanent breast seed implant (PBSI)
  189. Intravenous radiation
  190. Side effects of radiation therapy for breast cancer
  191. Breast Cancer Surgery
  192. Learn More
  193. Breast Reconstruction After Mastectomy
  194. What is breast reconstruction?
  195. How do surgeons use implants to reconstruct a woman's breast?
  196. How do surgeons use tissue from a woman's own body to reconstruct the breast?
  197. How do surgeons reconstruct the nipple and areola?
  198. What factors can affect the timing of breast reconstruction?
  199. What factors can affect the choice of breast reconstruction method?
  200. Will health insurance pay for breast reconstruction?
  201. What type of follow-up care and rehabilitation is needed after breast reconstruction?
  202. Does breast reconstruction affect the ability to check for breast cancer?
  203. What is flat closure?
  204. What are some new developments in breast reconstruction after mastectomy?
  205. Choosing Between a Lumpectomy and Mastectomy
  206. Are you facing a decision about lumpectomy vs. mastectomy?
  207. Compare lumpectomy and mastectomy
  208. Questions about the effectiveness of breast cancer surgery
  209. Which type of breast cancer surgery is best for my cancer?
  210. Will the type of breast cancer surgery I have affect how long I live?
  211. What are the chances that my breast cancer will return in the same area?
  212. Questions about recovering from breast cancer surgery
  213. Will I have pain?
  214. How long before I can return to normal activities?
  215. What other problems might I have from breast cancer surgery?
  216. Questions about treatment after breast surgery
  217. What other types of treatment might I need after breast cancer surgery?
  218. Will I need more surgery?
  219. Questions about body image and quality of life after breast cancer surgery
  220. What will my breast look like after breast cancer surgery?
  221. Will my breast have feeling after breast cancer surgery?
  222. Will the type of breast surgery I choose affect my quality of life?
  223. Think about what is important to you
  224. Lumpectomy (Breast-Conserving Surgery)
  225. Treatment before or after lumpectomy
  226. Recovering from lumpectomy
  227. Reconstruction after lumpectomy
  228. Lumpectomy risks
  229. Mastectomy
  230. Types of mastectomy
  231. Single vs. double mastectomy
  232. Mastectomy with breast reconstruction surgery
  233. Going flat after a mastectomy
  234. Recovering after a mastectomy
  235. Mastectomy risks
  236. Targeted Therapy for Breast Cancer
  237. Who gets targeted therapy for breast cancer?
  238. When is targeted therapy for breast cancer given?
  239. Targeted therapy for HER2-positive breast cancer
  240. Targeted therapy for hormone receptor–positive breast cancer
  241. Targeted therapy for triple-negative breast cancer
  242. Targeted therapy for BRCA-positive breast cancer
  243. Side effects of targeted therapy
  244. Triple-Negative Breast Cancer Treatment
  245. Treating stages I–III triple-negative breast cancer
  246. Treating metastatic or stage IV (also called stage 4) triple-negative breast cancer
  247. Treatment for recurrent triple-negative breast cancer
  248. Clinical trials

For patients · Immunotherapy for Breast Cancer

Side effects of immunotherapy

Source: Immunotherapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

The most common side effects of immunotherapy are rash, diarrhea, and fatigue, which is feeling exhausted or extremely tired. Learn more about the side effects of immunotherapy and steps you can take to manage or prevent them.

Sources: diarrhea · fatigue · side effects of immunotherapy

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

For patients

Inflammatory Breast Cancer Treatment

Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Different types of treatments are available for inflammatory breast cancer. You and your cancer care team will work together to decide on your treatment plan, which likely will include more than one type of treatment. Learn more about inflammatory breast cancer symptoms, diagnosis, and prognosis at Inflammatory Breast Cancer.

Sources: Inflammatory Breast Cancer

Inflammatory breast cancer is always diagnosed as either stage III or stage IV disease. Learn more about how breast cancer is staged at Breast Cancer Stages.

Sources: Breast Cancer Stages

For patients · Inflammatory Breast Cancer Treatment

Treating stage III (also called stage 3) inflammatory breast cancer

Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Treating stage III (also called stage 3) inflammatory breast cancer

Stage III inflammatory breast cancer is generally treated with a combination of chemotherapy, surgery to remove the tumor, and radiation therapy. Immunotherapy, targeted therapy, and hormone therapy may also be given, depending on whether the cancer has certain biomarkers.

Sources: chemotherapy · radiation therapy · Immunotherapy · targeted therapy · hormone therapy · biomarkers

Chemotherapy. For stage III inflammatory breast cancer, chemotherapy is often used to help shrink the tumor before surgery to remove it. When chemotherapy is given before surgery, it is called neoadjuvant chemotherapy. Neoadjuvant chemotherapy may also reduce the number of lymph nodes that need to be removed during surgery. Chemotherapy may also be given after surgery (called adjuvant chemotherapy). Learn more about Chemotherapy for Breast Cancer.

Sources: lymph nodes · Chemotherapy for Breast Cancer

Surgery. The standard type of surgery for inflammatory breast cancer is a modified radical mastectomy, which removes the entire breast and the lymph nodes under the arm. Since inflammatory breast cancer affects large areas of skin on the breast, lumpectomy (breast-conserving surgery) and skin-sparing mastectomy are not options. Learn more about Mastectomy.

Sources: modified radical mastectomy · lumpectomy · Mastectomy

Radiation therapy. After surgery, you will likely have radiation therapy to the chest wall where the breast was removed to reduce the chance of breast cancer returning in the breast or chest wall. Learn more about Radiation for Breast Cancer.

Sources: chest wall · Radiation for Breast Cancer

Hormone therapy. You may receive hormone therapy if the cancer tests positive for estrogen receptors and/or progesterone receptors. Hormone therapy may also be given when the hormone receptor status of the cancer is unknown. Hormone therapy for inflammatory breast cancer is typically started during or after radiation therapy. Learn more about Hormone Therapy for Breast Cancer.

Sources: estrogen receptors · progesterone receptors · hormone receptor status · Hormone Therapy for Breast Cancer

Immunotherapy. You may receive immunotherapy, such as pembrolizumab, if biomarker tests suggest that the cancer is triple-negative. Learn more about Immunotherapy for Breast Cancer.

Sources: pembrolizumab · triple-negative · Immunotherapy for Breast Cancer

Targeted therapy. You may receive targeted therapy, such as trastuzumab, if biomarker tests suggest that the cancer has certain biomarkers. Learn more about Targeted Therapy for Breast Cancer.

Sources: trastuzumab · biomarkers · Targeted Therapy for Breast Cancer

For patients · Inflammatory Breast Cancer Treatment

Treating metastatic or stage IV (also called stage 4) inflammatory breast cancer

Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Treating metastatic or stage IV (also called stage 4) inflammatory breast cancer

In metastatic (stage IV or stage 4) inflammatory breast cancer, the cancer has spread beyond the breast and nearby lymph nodes to distant parts of the body. Treatment for stage IV inflammatory breast cancer is the same as treatment for other types of metastatic breast cancer.

Learn more about treatment options at Metastatic Breast Cancer in the section, “How is metastatic breast cancer treated?”

Sources: Metastatic Breast Cancer

For patients · Inflammatory Breast Cancer Treatment

Treatment for recurrent inflammatory breast cancer

Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Treatment for recurrent inflammatory breast cancer

If cancer returns to the place where it began or nearby, it is called a locoregional recurrence. Treatment for locoregional recurrence of inflammatory breast cancer may include chemotherapy, surgery, and radiation. Other drugs may be added, depending on whether your cancer has certain biomarkers. Treatment for inflammatory breast cancer that has come back in distant parts of the body may be similar to treatment for stage IV breast cancer.

Sources: recurrence

Learn more about Breast Cancer Recurrence.

Sources: Breast Cancer Recurrence

For patients · Inflammatory Breast Cancer Treatment

Clinical trials

Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Clinical trials

Connect with a cancer information specialist at 1-800-4-CANCER, through live chat, or by email.

Joining a clinical trial may be an option. There are different types of clinical trials for people with breast cancer. For example, a treatment trial tests new treatments or new ways of using existing treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials that are accepting participants. This search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. You can also review a list of NCI-supported Breast Cancer Clinical Trials. Clinical trials supported by other organizations can be found at ClinicalTrials.gov.

Sources: clinical trial search · Breast Cancer Clinical Trials · ClinicalTrials.gov

Learn more about clinical trials at Cancer Clinical Trial Information for Patients and Caregivers.

Sources: Cancer Clinical Trial Information for Patients and Caregivers

For patients · Inflammatory Breast Cancer Treatment

Coping with inflammatory breast cancer treatment

Source: Inflammatory Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Coping with inflammatory breast cancer treatment

Treatment for inflammatory breast cancer can be mentally and physically challenging. It is important that you bring up any questions and concerns you have with your health care team throughout your care and treatment to get the support you need.

In addition to support from your health care team and family, one-on-one counseling or in-person and online support groups can help you cope and improve your mental wellbeing. Learn more about how to manage the physical and emotional effects of breast cancer at Living with Breast Cancer and Survivorship.

Sources: Living with Breast Cancer and Survivorship

For patients

Radiation for Breast Cancer

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Radiation therapy is a cancer treatment that uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Radiation is given in a series of treatments to allow healthy cells to recover and to make radiation more effective. The number of treatments is based on details about the cancer, such as the size and location of the tumor. Most of the time, radiation is given as an outpatient treatment. This means that you will have treatment at a clinic or radiation therapy center and will not stay overnight in the hospital.

Sources: x-rays · radiation · outpatient

For patients · Radiation for Breast Cancer

Types of radiation therapy for breast cancer

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Types of radiation therapy for breast cancer

External beam radiation therapy and brachytherapy (internal radiation therapy) are the main types of radiation therapy used for breast cancer. External beam radiation therapy comes from a machine that aims radiation at the cancer. For internal radiation therapy, the radiation source is placed inside the body near the cancer.

For patients · Radiation for Breast Cancer / Types of radiation therapy for breast cancer

External beam radiation therapy for breast cancer

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

External beam radiation therapy is a local treatment, which means it treats a specific part of your body. It may be given to the whole breast or chest, or to the part of the breast where the cancer is or where it was located before it was removed by surgery. Most of the time, you will get external beam radiation therapy as an outpatient.

To learn how to prepare for radiation therapy, visit the booklet Radiation Therapy and You: Support for People with Cancer.

Sources: Radiation Therapy and You: Support for People with Cancer

Radiation therapy for breast cancer usually begins about a month or two after surgery. That is because radiation therapy can slow wound healing. If you are also receiving chemotherapy, radiation therapy usually starts about a month after you have finished chemotherapy. You can have radiation at the same time as you are receiving some other treatments, such as hormone therapy or targeted therapy.

Sources: chemotherapy · hormone therapy · targeted therapy

For patients · Radiation for Breast Cancer / Types of radiation therapy for breast cancer / External beam radiation therapy for breast cancer

Whole breast radiation therapy

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

With this type of radiation therapy, an x-ray machine delivers radiation to either the whole breast, or, if done after mastectomy, to the entire chest wall. Sometimes, radiation will also target the lymph nodes in the armpit or neck area or under the breastbone. Most people have treatment once a day, Monday through Friday, for about 5 to 6 weeks. In some cases, it may be done in 4 weeks or less. Your doctor will recommend the treatment regimen that is right for you.

Sources: mastectomy · chest wall · lymph nodes

This type of cancer treatment comes from a machine that aims radiation at a specifc part of your body.

For patients · Radiation for Breast Cancer / Types of radiation therapy for breast cancer / External beam radiation therapy for breast cancer

Partial breast external beam radiation therapy

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Two techniques are commonly used to give external beam radiation treatment to the area where the cancer is or where it was located before it was removed by surgery:

Three-dimensional conformal external beam radiation (3DCRT) shapes the radiation beams to match the tumor’s shape, delivering a fixed dose of radiation from many directions.

Intensity-modulated radiation therapy (IMRT) also aims the radiation beams at the tumor from many directions. But IMRT also varies the intensity of radiation across the treatment area to allow higher doses of radiation to be given in areas needing more treatment and lower doses to be given in areas near sensitive organs or tissues.

Most people have treatment once a day, Monday through Friday, for 2 to 4 weeks.

Researchers are looking at other ways to adjust the radiation dose or schedule to reach the total dose of radiation more quickly or to limit damage to healthy cells.

Accelerated fractionation is treatment given in larger daily or weekly doses to reduce the number of weeks of treatment.

Sources: fractionation

Hyperfractionation is a smaller dose than the usual daily dose of radiation given more than once a day.

Sources: Hyperfractionation

Hypofractionation is larger doses given once a day or less often to reduce the number of treatments.

Sources: Hypofractionation

For patients · Radiation for Breast Cancer / Types of radiation therapy for breast cancer / External beam radiation therapy for breast cancer

Intraoperative radiation therapy

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Intraoperative radiation therapy is a type of external beam radiation therapy in which a single dose of radiation therapy is delivered to the tumor site during surgery.

For patients · Radiation for Breast Cancer / Types of radiation therapy for breast cancer

Brachytherapy for breast cancer

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Brachytherapy (also called internal radiation therapy) is sometimes used after breast-conserving surgery. It involves placing radioactive material using seeds, pellets, or needles in the area where the cancer was removed. The radiation only reaches a small area around the surgical site, where the risk of recurrence is highest.

Sources: breast-conserving surgery

For patients · Radiation for Breast Cancer / Types of radiation therapy for breast cancer / Brachytherapy for breast cancer

Intracavitary brachytherapy

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Intracavitary brachytherapy is the most common type of brachytherapy for breast cancer. In this form of brachytherapy, a balloon, applicator, or similar device is inserted into the space where the cancer was, either during or a few days after breast-conserving surgery. A radioactive pellet is placed into the device during each treatment session and then removed after each treatment.

Treatments usually last about 5 to 10 minutes and are given 2 times a day for 5 days. After about 2 weeks, the device is removed. You may need stitches to close the hole when treatment is complete.

For patients · Radiation for Breast Cancer / Types of radiation therapy for breast cancer / Brachytherapy for breast cancer

Interstitial brachytherapy

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

In interstitial brachytherapy, several small tubes, called catheters, are inserted into the tissue where the breast cancer was and stitched in place. This is most often done 1 to 2 weeks after surgery. A radiation source, such as radioactive pellets or seeds, is temporarily placed into the catheters during each treatment session. Treatments usually last about 20 minutes. Two kinds of sources, high-dose implants and low-dose implants, can be used:

High-dose implants: If you receive high-dose implants, the radiation is delivered once or twice a day for about 5 days. You will be able to leave the hospital after each treatment, and you will not remain radioactive after. It is safe to be around others, including babies and children.

Low-dose implants: If you receive low-dose implants, treatment can be delivered over several hours to days. The radiation source stays in place and is slowly delivered to the tissue around the catheters. You will stay in the hospital throughout treatment to avoid exposing others to radiation. The radiation source and catheters are removed when treatment is complete. Then you can go home.

For patients · Radiation for Breast Cancer / Types of radiation therapy for breast cancer / Brachytherapy for breast cancer

Permanent breast seed implant (PBSI)

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

PBSI involves placing permanent radioactive seeds into the breast tissue around the area where the cancer was removed. The seeds emit radiation at a low dose. Although the seeds remain in the body, they lose their radioactivity over time and do not need to be removed. This is a one-time procedure that usually does not require a hospital stay.

For patients · Radiation for Breast Cancer / Types of radiation therapy for breast cancer / Brachytherapy for breast cancer

Intravenous radiation

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Intravenous radiation with strontium-89 (a radionuclide) is given as palliative therapy to relieve bone pain caused by breast cancer that has spread to the bones. Strontium-89 is injected into a vein and travels to the surface of the bones. Radiation is released and kills cancer cells in the bones.

Sources: radionuclide

Learn more about Brachytherapy to Treat Cancer.

Sources: Brachytherapy to Treat Cancer

For patients · Radiation for Breast Cancer

Side effects of radiation therapy for breast cancer

Source: Radiation for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Side effects of radiation therapy for breast cancer

Radiation kills or slows the growth of cancer cells and can also affect nearby healthy cells. Damage to healthy cells can cause side effects. Your experience may be different from someone else who is getting the same amount of radiation therapy to the same part of the body. Sometimes, people may have side effects that do not improve.

Possible early side effects of radiation therapy for breast cancer include:

fatigue (feeling exhausted and worn out)

Sources: fatigue

hair loss in the area exposed to radiation

Sources: hair loss

skin changes, such as redness and dryness, in the area exposed to radiation

Sources: skin changes

breast tenderness or hardening

Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects.

Possible late effects of radiation therapy for breast cancer include:

skin changes, such as redness and dryness, in the area exposed to radiation

breast pain, tenderness, or hardening

heart and lung problems

bone weakness

lymphedema

Sources: lymphedema

second cancers, rarely

Learn more about Late Effects of Cancer Treatment.

Sources: Late Effects of Cancer Treatment

Discuss potential side effects with your doctor or nurse so you know what to expect during and after treatment. Regular follow-up care and supportive care can help manage side effects that do occur.

Learn more about Living with Breast Cancer and Survivorship.

Sources: Living with Breast Cancer and Survivorship

For patients

Breast Cancer Surgery

Source: Breast Cancer Surgery, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Most people with breast cancer or ductal carcinoma in situ (DCIS) will have surgery to remove the tumor and nearby breast tissue. The two main types of surgery are lumpectomy (breast-conserving surgery) and mastectomy, with or without breast reconstruction.

Sources: ductal carcinoma in situ · tissue · lumpectomy · mastectomy · breast reconstruction

Breast cancer surgery may also involve checking nearby lymph nodes for cancer. Usually, a sentinel lymph node biopsy is done, often during a lumpectomy or mastectomy but sometimes as a separate surgery. Learn more about sentinel lymph node biopsy at How Breast Cancer Is Diagnosed.

Sources: lymph nodes · sentinel lymph node biopsy · How Breast Cancer Is Diagnosed

For patients · Breast Cancer Surgery

Learn More

Source: Breast Cancer Surgery, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Lumpectomy (Breast-Conserving Surgery) Learn about lumpectomy, additional treatments you may need, your options for reconstruction, and lumpectomy risks.

Sources: Lumpectomy (Breast-Conserving Surgery) Learn about lumpectomy, additional treatments you may need, your options for reconstruction, and lumpectomy risks.

Mastectomy Learn about different types of mastectomies, additional treatments you may need, your options for reconstruction, and mastectomy risks.

Sources: Mastectomy Learn about different types of mastectomies, additional treatments you may need, your options for reconstruction, and mastectomy risks.

Lumpectomy vs. Mastectomy Get answers to common questions about lumpectomy and mastectomy that can help you choose an option that is right for you.

Sources: Lumpectomy vs. Mastectomy Get answers to common questions about lumpectomy and mastectomy that can help you choose an option that is right for you.

Breast Reconstruction After Mastectomy Learn about your options for breast reconstruction, including types of reconstruction and factors that may affect your choice.

Sources: Breast Reconstruction After Mastectomy Learn about your options for breast reconstruction, including types of reconstruction and factors that may affect your choice.

For patients

Breast Reconstruction After Mastectomy

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

For patients · Breast Reconstruction After Mastectomy

What is breast reconstruction?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

What is breast reconstruction?

Many women who have a mastectomy—surgery to remove an entire breast to treat or prevent breast cancer—have the option of having the shape of the removed breast rebuilt. Some people choose not to have their breasts reconstructed after a mastectomy, instead preferring a flat closure.

Sources: flat closure

Breasts can be rebuilt using implants (saline or silicone) or autologous tissue (that is, tissue from elsewhere in the body). Sometimes both implants and autologous tissue are used to rebuild the breast.

Sources: saline · silicone · autologous

Surgery to reconstruct the breasts can be done (or started) at the time of the mastectomy, called immediate reconstruction, or it can be done after the mastectomy incisions have healed and treatment has been completed, called delayed reconstruction. Delayed reconstruction can happen months or even years after the mastectomy.

In the final stage of breast reconstruction, a nipple and areola may be re-created on the reconstructed breast, if these were not preserved during the mastectomy.

Sources: nipple · areola

Sometimes breast reconstruction surgery includes surgery on the other, or contralateral, breast so that the two breasts will match in size and shape.

Sources: contralateral

For patients · Breast Reconstruction After Mastectomy

How do surgeons use implants to reconstruct a woman's breast?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

How do surgeons use implants to reconstruct a woman's breast?

Implants are inserted underneath the skin or chest muscle following the mastectomy. Implants are usually placed as part of a two-stage procedure.

In the first stage, the surgeon places a device called a tissue expander under the skin that is left after the mastectomy or under the chest muscle (1, 2). The expander is slowly filled with saline or air during periodic visits to the doctor after surgery.

Sources: 1 · 2 · saline

In the second stage, after the chest tissue has relaxed and healed enough, the expander is removed and replaced with an implant. The chest tissue is usually ready for the implant 2 to 6 months after the tissue expander is placed.

In some cases, the implant can be placed in the breast during the same surgery as the mastectomy—that is, a tissue expander is not used (3).

Sources: 3

Surgeons are increasingly using material called acellular dermal matrix as a kind of scaffold or “sling” to support tissue expanders and implants. Acellular dermal matrix is a kind of mesh that is made from donated human or pig skin that has been sterilized and processed to remove all cells to eliminate the risks of rejection and infection.

For patients · Breast Reconstruction After Mastectomy

How do surgeons use tissue from a woman's own body to reconstruct the breast?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

How do surgeons use tissue from a woman's own body to reconstruct the breast?

In autologous tissue reconstruction, a piece of tissue containing skin, fat, blood vessels, and sometimes muscle is taken from elsewhere in a woman’s body and used to rebuild the breast. This piece of tissue is called a flap.

Sources: autologous

Different sites in the body can provide flaps for breast reconstruction. Flaps most often come from the abdomen or back. However, they can also be taken from the thigh or buttocks.

Sources: abdomen

Depending on their source, flaps can be pedicled or free.

With a pedicled flap, the tissue and attached blood vessels are moved together through the body to the breast area. Because the blood supply to the tissue used for reconstruction is left intact, blood vessels do not need to be reconnected once the tissue is moved.

Sources: pedicled flap

With free flaps, the tissue is cut free from its blood supply. It must be attached to new blood vessels in the breast area, using a technique called microsurgery, to give the reconstructed breast a blood supply.

Sources: free flaps

Abdominal and back flaps include:

DIEP flap: Tissue comes from the abdomen and contains only skin, blood vessels, and fat, without the underlying muscle. This type of flap is a free flap.

Sources: DIEP flap · free flap

Latissimus dorsi (LD) flap: Tissue comes from the middle and side of the back. This type of flap is pedicled when used for breast reconstruction. (LD flaps can also be used for other types of reconstruction, such as abdominal or head and neck reconstruction.)

SIEA flap (also called SIEP flap): Tissue comes from the abdomen as in a DIEP flap but includes a different set of blood vessels. It also does not involve cutting of the abdominal muscle and is a free flap. This type of flap is not usually an option for breast reconstruction because the necessary blood vessels are often not adequate or do not exist.

TRAM flap: Tissue comes from the lower abdomen as in a DIEP flap but includes muscle. TRAM flaps can be either pedicled or free.

Sources: TRAM flap

Flaps taken from the thigh or buttocks are used for women who have had previous major abdominal surgery or who don’t have enough abdominal tissue to reconstruct a breast. These types of flaps are free flaps.

IGAP flap: Tissue comes from the buttocks and contains only skin, blood vessels, and fat.

PAP flap: Tissue, without muscle, comes from the upper inner thigh.

SGAP flap: Tissue comes from the buttocks as in an IGAP flap but includes a different set of blood vessels and contains only skin, blood vessels, and fat.

TUG flap: Tissue, including muscle, comes from the upper inner thigh.

The table below summarizes the different types of flaps used for breast reconstruction:

Source table; cell spans preserved from the original.
Name of flapType of flapSource of tissueIncludes muscle?
DIEPFreeAbdomenNo
Latissumus dorsiPedicledMiddle and side of backYes
SIEA/SIEPFreeAbdomenNo
TRAMPedicled or freeLower abdomenYes
IGAPFreeButtocksNo
PAPFreeUpper inner thighNo
SGAPFreeButtocksNo
TUGFreeUpper inner thighYes

In some cases, an implant and autologous tissue are used together. For example, with flaps taken from the thigh or buttocks an implant is often used as well to provide sufficient breast volume. Also, autologous tissue may be used to cover an implant when there isn’t enough skin and muscle left after mastectomy to allow for expansion and use of an implant (1, 2).

Sources: 1 · 2

For patients · Breast Reconstruction After Mastectomy

How do surgeons reconstruct the nipple and areola?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

How do surgeons reconstruct the nipple and areola?

After the chest heals from reconstruction surgery and the position of the breast mound on the chest wall has had time to stabilize, the nipple and areola can be reconstructed. This can be done in two ways—surgically or with tattoos.

Sources: chest wall · nipple · areola

For surgical nipple reconstruction, the new nipple is created by cutting and moving small pieces of skin from the reconstructed breast to the nipple site and shaping them into a new nipple. A few months later, the surgeon can re-create the areola. This is usually done using tattoo ink.

However, in some cases, skin grafts may be taken from the groin or abdomen and attached to the breast to create an areola at the time of the nipple reconstruction (1).

Sources: skin grafts · 1

Alternatively, a new nipple and areola can be created by a tattoo artist who specializes in 3-D nipple tattooing. Such a nipple is flat to the touch but looks realistic.

Sources: 3-D

A mastectomy that preserves a woman's own nipple and areola, called nipple-sparing mastectomy, may be an option for some women, depending on the size and location of the breast cancer and the shape and size of the breasts (4, 5).

Sources: 4 · 5

For patients · Breast Reconstruction After Mastectomy

What factors can affect the timing of breast reconstruction?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

What factors can affect the timing of breast reconstruction?

One factor that can affect the timing of breast reconstruction is whether a woman will need radiation therapy. Radiation therapy can sometimes cause wound healing problems or infections in reconstructed breasts, so some women may prefer to delay reconstruction until after radiation therapy is completed. However, because of improvements in surgical and radiation techniques, immediate reconstruction with an implant is usually still an option for women who will need radiation therapy. Autologous tissue breast reconstruction is usually reserved for after radiation therapy, so that the breast and chest wall tissue damaged by radiation can be replaced with healthy tissue from elsewhere in the body.

Sources: radiation therapy · Autologous · chest wall

Even if a woman is a candidate for immediate reconstruction, she may choose delayed reconstruction. For instance, some women prefer not to consider what type of reconstruction to have until after they have recovered from their mastectomy and subsequent adjuvant treatment. Women who delay reconstruction (or choose not to undergo the procedure at all) can use external breast prostheses, or breast forms, to give the appearance of breasts.

For patients · Breast Reconstruction After Mastectomy

What factors can affect the choice of breast reconstruction method?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

What factors can affect the choice of breast reconstruction method?

Several factors can influence the type of reconstructive surgery a woman chooses. These include the size and shape of the breast that is being rebuilt, the woman’s age and health, her history of past surgeries, her risk factors for complications after surgery (for example, smoking history and obesity), the availability of autologous tissue, and the location of the tumor in the breast (2, 6). Women who have had past abdominal surgery may not be candidates for an abdominally based flap reconstruction.

Sources: reconstructive surgery · risk factors · complications · autologous · 2 · 6

Each type of reconstruction has factors that a woman should think about before making a decision. Some of the more common considerations are listed below.

Reconstruction with Implants

Surgery and recovery

Enough skin and muscle must remain after mastectomy to cover the implant

Shorter surgical procedure than for reconstruction with autologous tissue; little blood loss

Recovery period may be shorter than with autologous reconstruction

Many follow-up visits may be needed to inflate the expander and insert the implant

Possible complications

Infection

Accumulation of clear fluid causing a mass or lump (seroma) within the reconstructed breast (7)

Sources: seroma · 7

Pooling of blood (hematoma) within the reconstructed breast

Sources: hematoma

Blood clots

Sources: Blood clots

Extrusion of the implant (the implant breaks through the skin)

Implant rupture (the implant breaks open and saline or silicone leaks into the surrounding tissue)

Sources: saline · silicone

Formation of hard scar tissue around the implant (known as a contracture)

Sources: contracture

Obesity, diabetes, and smoking may increase the rate of complications

Sources: diabetes

Very small risk of developing a very rare form of immune system cancer called breast implant associated–anaplastic large cell lymphoma, particularly with textured implants

Sources: breast implant associated–anaplastic large cell lymphoma

A small number of squamous cell carcinomas and various lymphomas in the scar tissue around implants have been reported, but they are very rare

Sources: squamous cell carcinomas and various lymphomas

Other considerations

May not be an option for patients who have previously undergone radiation therapy to the chest

Sources: radiation therapy

May not be adequate for women with very large breasts

Will not last a lifetime; the longer a woman has implants, the more likely she is to have complications and to need to have her implants removed or replaced

Silicone implants may feel more natural than saline implants to the touch

The Food and Drug Administration (FDA) recommends that women with silicone implants undergo periodic MRI screenings to detect possible “silent” rupture of the implants

Sources: MRI

More information about implants can be found on FDA’s Breast Implants page.

Sources: Breast Implants

Reconstruction with Autologous Tissue

Surgery and recovery

Longer surgical procedure than for implants

The initial recovery period may be longer than for implants

Pedicle flap reconstruction is usually a shorter operation than free flap reconstruction and usually requires a shorter hospitalization

Sources: free flap

Free flap reconstruction is a highly technical operation that requires a surgeon who has experience with microsurgery to reattach blood vessels.

Possible complications

Necrosis (death) of the transferred tissue

Sources: Necrosis

The risk of bleeding and blood clots is higher with autologous reconstruction than with implants

Pain and weakness at the site from which the donor tissue was taken

Obesity, diabetes, and smoking may increase the rate of complications

Other considerations

May provide a more natural breast shape than implants

May feel softer and more natural to the touch than implants

Leaves a scar at the site from which the donor tissue was taken

Can be used to replace tissue that has been damaged by radiation therapy

Sources: radiation therapy

All women who undergo mastectomy for breast cancer experience varying degrees of numbness and loss of feeling in the breast because nerves that provide sensation to the breast are cut when breast tissue is removed during surgery. However, some breast sensation may be regained as the severed nerves grow and regenerate, and breast surgeons continue to make technical advances that can spare or repair damage to nerves.

Any type of breast reconstruction can fail if healing does not occur properly. In these cases, the implant or flap will have to be removed. If an implant reconstruction fails, a woman can usually have a second reconstruction using an alternative approach.

For patients · Breast Reconstruction After Mastectomy

Will health insurance pay for breast reconstruction?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Will health insurance pay for breast reconstruction?

The Women’s Health and Cancer Rights Act of 1998 (WHCRA) is a federal law that requires group health plans and health insurance companies that offer mastectomy coverage to also pay for reconstructive surgery after mastectomy. This coverage must include all stages of reconstruction and surgery to achieve symmetry between the breasts, breast prostheses, and treatment of complications that result from the mastectomy, including lymphedema. More information about WHCRA is available from the Department of Labor and the Centers for Medicare & Medicaid Services.

Sources: reconstructive surgery · complications · lymphedema · Department of Labor · Centers for Medicare & Medicaid Services

Some health plans sponsored by religious organizations and some government health plans may be exempt from WHCRA. Also, WHCRA does not apply to Medicare or Medicaid. However, Medicare may cover breast reconstruction surgery as well as external breast prostheses (including a post-surgical bra) after a medically necessary mastectomy. Medicaid benefits vary by state; a woman should contact her state Medicaid office for information on whether, and to what extent, breast reconstruction is covered.

Sources: Medicare

A woman considering breast reconstruction may want to discuss costs and health insurance coverage with her doctor and insurance company before choosing to have the surgery. Some insurance companies require a second opinion before they will agree to pay for a surgery.

Sources: second opinion

For patients · Breast Reconstruction After Mastectomy

What type of follow-up care and rehabilitation is needed after breast reconstruction?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

What type of follow-up care and rehabilitation is needed after breast reconstruction?

Any type of reconstruction increases the number of side effects a woman may experience compared with those after a mastectomy alone. A woman’s medical team will watch her closely for complications, some of which can occur months or even years after surgery (1, 2, 8).

Sources: side effects · complications · 1 · 2 · 8

Women who have breast reconstruction may benefit from physical therapy to improve or maintain shoulder range of motion or help recover from weakness experienced at the site from which donor tissue was taken for an autologous reconstruction (9, 10). A physical therapist can help a woman use exercises to regain strength, adjust to new physical limitations, and figure out the safest ways to perform everyday activities.

Sources: physical therapy · 9 · 10 · physical therapist

For patients · Breast Reconstruction After Mastectomy

Does breast reconstruction affect the ability to check for breast cancer?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Does breast reconstruction affect the ability to check for breast cancer?

Mammography is not typically done on a breast that is reconstructed after mastectomy; instead, physical exams are done to check for recurrence. However, women who have one breast removed by mastectomy will still have mammograms of the other breast.

Sources: Mammography · physical exams · recurrence

For patients · Breast Reconstruction After Mastectomy

What is flat closure?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

What is flat closure?

A flat closure (also called aesthetic flat closure) is surgery done to rebuild the shape of the chest wall after the removal of one or both breasts. It is also a surgical option for people who have had their breast implants removed.

Sources: aesthetic flat closure · chest wall

During an aesthetic flat closure, a surgeon removes extra skin, fat, and other tissue in the breast area. The remaining tissue is then tightened and smoothed out so that the chest wall appears flat and contoured. Simply forgoing additional procedures to reconstruct the breast(s) after a mastectomy will not achieve a flat closure (11).

Sources: 11

For patients · Breast Reconstruction After Mastectomy

What are some new developments in breast reconstruction after mastectomy?

Source: Breast Reconstruction After Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

What are some new developments in breast reconstruction after mastectomy?

Oncoplastic surgery. In general, women who have lumpectomy or partial mastectomy for early-stage breast cancer do not have reconstruction. However, in some cases the surgeon may use plastic surgery techniques to reshape the breast at the time of cancer surgery. This type of breast-conserving surgery, called oncoplastic surgery, may use local tissue rearrangement, reconstruction through breast reduction surgery, or transfer of tissue flaps. Long-term outcomes of this type of surgery are comparable to those for standard breast-conserving surgery (12).

Sources: lumpectomy · partial mastectomy · early-stage breast cancer · plastic surgery · breast-conserving surgery · 12

Autologous fat grafting. A newer type of breast reconstruction technique involves the transfer of fat tissue from one part of the body (usually the thighs, abdomen, or buttocks) to the reconstructed breast. The fat tissue is harvested by liposuction, washed, and liquified so that it can be injected into the area of interest. Fat grafting is mainly used to correct deformities and asymmetries that may appear after breast reconstruction. It is also sometimes used to reconstruct an entire breast. Although concern has been raised about the lack of long-term outcome studies, this technique is considered safe (1, 6, 13).

Sources: liposuction · 1 · 6 · 13

For patients

Choosing Between a Lumpectomy and Mastectomy

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

For patients · Choosing Between a Lumpectomy and Mastectomy

Are you facing a decision about lumpectomy vs. mastectomy?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Are you facing a decision about lumpectomy vs. mastectomy?

Do you have ductal carcinoma in situ (DCIS) or breast cancer that can be removed with surgery? If so, you may be able to choose which type of breast surgery you have. Often, your choice is between a lumpectomy or other breast-conserving surgery (surgery that takes out the cancer and leaves most of the breast) and a mastectomy (surgery that removes the whole breast).

Sources: ductal carcinoma in situ · lumpectomy · mastectomy

Learn more about these surgeries at Breast Cancer Surgery.

Sources: Breast Cancer Surgery

Once you are diagnosed, treatment will usually not begin right away. Use the time to:

talk with your doctor

get a second opinion

check with your insurance company

learn the facts about your surgery choices

think about what is important to you

For patients · Choosing Between a Lumpectomy and Mastectomy

Compare lumpectomy and mastectomy

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Compare lumpectomy and mastectomy

If your surgeon gives you a choice about which surgery to have, it can be hard to decide which one is best for you. This section can help you compare the different surgeries. Learn how the surgeries are alike and how they are different by clicking on each question to learn more.

Which type of breast cancer surgery is best for my cancer?

Sources: Which type of breast cancer surgery is best for my cancer?

Will the type of surgery I have affect how long I live?

Sources: Will the type of surgery I have affect how long I live?

What are the chances that my breast cancer will return in the same area?

Sources: What are the chances that my breast cancer will return in the same area?

Will I have pain?

Sources: Will I have pain?

How long before I can return to normal activities?

Sources: How long before I can return to normal activities?

What other problems might I have from the surgery?

Sources: What other problems might I have from the surgery?

What other types of treatment might I need?

Sources: What other types of treatment might I need?

Will I need more surgery?

Sources: Will I need more surgery?

What will my breast look like after surgery?

Sources: What will my breast look like after surgery?

Will my breast have feeling after surgery?

Sources: Will my breast have feeling after surgery?

Will the type of surgery I choose affect my quality of life?

Sources: Will the type of surgery I choose affect my quality of life?

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy

Questions about the effectiveness of breast cancer surgery

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about the effectiveness of breast cancer surgery

Which type of breast cancer surgery is best for my cancer?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Source table; cell spans preserved from the original.
Lumpectomy or other breast-conserving surgeryMost women with DCIS or breast cancer can choose to have a lumpectomy (breast-conserving surgery), usually followed by radiation therapy.
MastectomyMost women with DCIS or breast cancer can choose to have a mastectomy. A mastectomy may be a better choice for you if:you have small breasts and a large area of DCIS or canceryou have DCIS or cancer in more than one part of your breastthe DCIS or cancer is under the nippleyou are not able or prefer not to receive radiation therapy
Mastectomy with reconstructionIf you have a mastectomy, you might also want breast reconstruction surgery. You can choose to have reconstruction surgery at the same time as your mastectomy or wait and have it later. Your surgeon can talk with you about how much skin, including the nipple and areola, might be preserved for reconstruction.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about the effectiveness of breast cancer surgery

Will the type of breast cancer surgery I have affect how long I live?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

No. Research shows that women who have breast-conserving surgery live as long as women who have a mastectomy. This does not change if you also have reconstruction.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about the effectiveness of breast cancer surgery

What are the chances that my breast cancer will return in the same area?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Source table; cell spans preserved from the original.
Lumpectomy or other breast-conserving surgeryThere is a chance that your cancer will come back in the same breast if you have a lumpectomy. But if it does, it is not likely to affect how long you live. About 5% to 10% of women (1 out of every 10 to 20) who have a lumpectomy followed by radiation therapy get cancer in the same breast within 12 years. If this happens, you can be effectively treated with a mastectomy.
MastectomyThere is a chance that your cancer will return in the same breast that was removed. This is called a local recurrence. It can happen after a mastectomy because surgeons cannot remove every bit of breast tissue. Also, the cancer can come back in the chest muscle or chest wall.Local recurrence is slightly less likely after mastectomy than after lumpectomy. About 1 out of every 20 women who have a mastectomy will get cancer on the same side of their chest within 12 years.
Mastectomy with reconstructionYour chances are the same as mastectomy because breast reconstruction surgery does not affect the chances of the cancer returning.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy

Questions about recovering from breast cancer surgery

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about recovering from breast cancer surgery

Will I have pain?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Most people have some pain after surgery. Talk with your doctor or nurse before surgery about ways to control pain after surgery. Also, tell them if your pain control is not working.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about recovering from breast cancer surgery

How long before I can return to normal activities?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Source table; cell spans preserved from the original.
Lumpectomy or other breast-conserving surgeryMost women are ready to return to most of their usual activities within 2 weeks.
MastectomyIt may take 3 to 4 weeks to feel mostly normal after a mastectomy.
Mastectomy with reconstructionYour recovery will depend on the type of reconstruction you have. It can take 6 to 8 weeks or longer to fully recover from a mastectomy that is followed by breast reconstruction.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about recovering from breast cancer surgery

What other problems might I have from breast cancer surgery?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Source table; cell spans preserved from the original.
Lumpectomy or other breast-conserving surgeryYou may feel very tired and have skin changes from radiation therapy.
MastectomyYou may feel out of balance if you had large breasts and do not have reconstruction surgery. This may also lead to neck and shoulder pain.
Mastectomy with reconstructionYou may not like how your breast-like shape looks. If you have an implant, your breast may harden and can become painful. If your implant breaks or leaks you may need more surgery. If you have tissue flap reconstruction, you may lose strength in the part of your body where a muscle was removed.

Sources: tissue flap reconstruction

If lymph nodes are removed from under your arm, you may develop lymphedema. Learn more about Lymphedema.

Sources: lymph nodes · Lymphedema

Learn about local and systemic treatments and access in-depth information about each type of treatment.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy

Questions about treatment after breast surgery

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about treatment after breast surgery

What other types of treatment might I need after breast cancer surgery?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

If you choose to have a lumpectomy or other breast-conserving surgery, you will usually need radiation therapy. Radiation treatments are often given 5 days a week for up to 6 weeks.

Sources: radiation therapy

If you have a mastectomy, you may still need radiation therapy.

No matter which surgery you choose, you might need:

chemotherapy

Sources: chemotherapy

hormone therapy

Sources: hormone therapy

targeted therapy

Sources: targeted therapy

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about treatment after breast surgery

Will I need more surgery?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Source table; cell spans preserved from the original.
Lumpectomy or other breast-conserving surgeryAfter surgery, if there are cancer cells at the edge of the removed breast tissue, then you may need more surgery to make sure that all the cancer is removed.
MastectomyIf you have problems after your mastectomy, you may need more surgery.
Mastectomy with reconstructionYou will most likely need more than one surgery to build a new breast-like shape. The number of surgeries you need will depend on the type of reconstruction you have and if you choose to have a nipple or areola added.Some women may also decide to have surgery on the opposite breast to help it better match the reconstructed breast.If you have an implant, you are likely to need surgery many years later to remove or replace it.

With all three surgeries, you may need more surgery to remove lymph nodes from under your arm to see how far the cancer has spread.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy

Questions about body image and quality of life after breast cancer surgery

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about body image and quality of life after breast cancer surgery

What will my breast look like after breast cancer surgery?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Source table; cell spans preserved from the original.
Lumpectomy or other breast-conserving surgeryYour breast should look a lot like it did before surgery.But if your tumor is large, your breast may look different or smaller after breast-conserving surgery.You will have a small scar where the surgeon cut to remove the DCIS or cancer. The length of the scar will depend on how large the incision was.
MastectomyIf you have a mastectomy without reconstruction, your breast and nipple will be removed. You will have a flat chest on the side of your body where the breast was removed.You will have a scar over the place where your breast was removed. The length of the scar will depend on the size of your breast. The scar is usually shorter for smaller breasts and longer for larger breasts.
Mastectomy with reconstructionIf you have a skin- or nipple-sparing mastectomy, your skin and nipple will remain after surgery. You will not have the sensation of temperature or touch, but your nipple will still react to these.Even if you have reconstruction, your breast shape will not look or feel like it did before surgery. And it will not look or feel like your other breast. You will have scars where the surgeon stitched skin together to make the new breast-like shape. If you have tissue flap reconstruction, you will have scars around the new breast, as well as in the area where the surgeon removed the muscle, fat, and skin to make the new breast-like shape.

With all three surgeries, the scars left from where the surgeon cut the skin and stitched it back together tend to fade over time.

To get a better idea of what to expect from surgery, ask your surgeon if you can see before and after pictures of other people who have had different types of surgery.

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about body image and quality of life after breast cancer surgery

Will my breast have feeling after breast cancer surgery?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Source table; cell spans preserved from the original.
Lumpectomy or other breast-conserving surgeryYes. You should still have feeling in your breast, nipple, and areola.
MastectomyMaybe. After surgery, the skin around where the surgeon cut and maybe the area under your arm will be numb. This numb feeling may improve over 1 to 2 years, but it will never feel like it once did. Also, the skin where your breast was may feel tight.
Mastectomy with reconstructionNo. Most of the area around your breast will not have feeling.

Some surgeons are trying new techniques to preserve or restore breast feeling after a mastectomy. Find clinical trials studying this issue using our NCI-supported clinical trials search or ClinicalTrials.gov.

Sources: clinical trials search · ClinicalTrials.gov

For patients · Choosing Between a Lumpectomy and Mastectomy / Compare lumpectomy and mastectomy / Questions about body image and quality of life after breast cancer surgery

Will the type of breast surgery I choose affect my quality of life?

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Research suggests that women who have breast-conserving surgery have a better long-term quality of life than those who have a mastectomy.

Sources: have a better long-term quality of life than those who have a mastectomy

For patients · Choosing Between a Lumpectomy and Mastectomy

Think about what is important to you

Source: Choosing Between a Lumpectomy and Mastectomy, National Cancer Institute.

Source updated: December 2, 2025. Captured 2026-09-09.

Think about what is important to you

After you have talked with a breast surgeon and learned the facts, you may also want to talk with your spouse or partner, family, friends, or other women who have had breast cancer surgery.

Then, think about what is important to you. Thinking about the following questions and talking them over with others might help:

If I have a lumpectomy or other breast-conserving surgery, am I willing and able to have radiation therapy 5 days a week for up to 6 weeks?

If I have a lumpectomy and the cancer comes back later in the same breast, how would I feel about needing a mastectomy?

If I have a mastectomy, do I also want breast reconstruction surgery?

If I have breast reconstruction surgery, do I want it at the same time as the mastectomy?

What treatment does my insurance cover? What do I have to pay for?

How important is it to me how my breast looks after cancer surgery?

How important is it to me how my breast feels after cancer surgery?

If I have a mastectomy and do not have reconstruction, will my insurance cover prostheses and special bras?

Where can I find breast prostheses and special bras?

Do I want a second opinion?

Is there someone else I should talk with about my surgery choices?

What else do I want to learn or do before I decide about breast cancer surgery?

For patients

Lumpectomy (Breast-Conserving Surgery)

Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Lumpectomy is a type of breast surgery in which the surgeon removes the ductal carcinoma in situ (DCIS) or breast cancer and some healthy tissue around it. If the cancer is near the chest wall, part of the chest wall lining may also be removed.

Sources: ductal carcinoma in situ · breast cancer · tissue · chest wall

Lumpectomy is an option for some people with DCIS or invasive breast cancer. It is usually followed by radiation therapy. Research shows that lumpectomy plus radiation therapy is just as effective as mastectomy (surgery to remove all breast tissue) at lowering your chance of dying from breast cancer or of the cancer coming back. Learn more about choosing between a mastectomy and lumpectomy to treat breast cancer.

Sources: radiation therapy · mastectomy · Learn more about choosing between a mastectomy and lumpectomy to treat breast cancer.

Your doctor may suggest a lumpectomy plus radiation therapy if:

the cancer or DCIS is small relative to the size of the breast

the cancer or DCIS is found in only one place in the breast

you are not pregnant and are able to have daily radiation therapy for up to 6 weeks

If large amounts of tissue need to be removed during a lumpectomy, the surgery may be called partial mastectomy, segmental mastectomy, or quadrantectomy.

After a lumpectomy, a pathologist will check the healthy tissue that was removed to see if it contains DCIS or cancer. If it does, you may need more surgery or a mastectomy so the surgeon can remove more tissue and make sure no DCIS or cancer cells remain in the breast.

Sources: pathologist

For patients · Lumpectomy (Breast-Conserving Surgery)

Treatment before or after lumpectomy

Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Most people who have a lumpectomy receive radiation therapy after they heal from surgery. The goal of this treatment is to keep cancer from coming back in the same breast. Learn more about Radiation for Breast Cancer.

Sources: Radiation for Breast Cancer

You might also need chemotherapy, hormone therapy, or targeted therapy, before or after surgery. Learn more about Breast Cancer Treatment.

Sources: chemotherapy · hormone therapy · targeted therapy · Breast Cancer Treatment

The type of treatment you receive will depend on many factors, such as how different the tumor cells look from normal breast cells, how likely the tumor cells are to grow and spread, and the results of biomarker tests. Learn more at How Breast Cancer Is Diagnosed and Tests for Breast Cancer Biomarkers.

Sources: cells · biomarker · How Breast Cancer Is Diagnosed · Tests for Breast Cancer Biomarkers

For patients · Lumpectomy (Breast-Conserving Surgery)

Recovering from lumpectomy

Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Most people can go home the day of their lumpectomy and go about their daily activities with few restrictions. But you may need help with some tasks, depending on the extent of your surgery. Within two weeks, you should be able to return to your normal activities.

For patients · Lumpectomy (Breast-Conserving Surgery)

Reconstruction after lumpectomy

Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

After a lumpectomy, your breast will usually look and feel much like it did before surgery. You will have a scar at the site of surgery. And there may be a dent where the tumor and tissue were removed.

Talk to your surgical team about how your surgery might change how your breast looks. If you think you will not be happy with the look or feel of your breast after surgery, you may think about reconstruction. Reconstruction can take place during or any time after the lumpectomy.

There are two types of breast reconstruction for people who have a lumpectomy:

Oncoplastic surgery combines lumpectomy with plastic surgery that can help make the breasts look more even if large amounts of tissue are removed from one breast. It can also reduce scarring and dents. A plastic surgeon will often do this reconstruction during the same surgery as the lumpectomy.

Sources: plastic surgery

Revision reconstruction usually happens after you have healed from a lumpectomy. A plastic surgeon may be able to improve scarring and hardening of tissue at the surgical site. And they may be able to restore the shape of the breast with fat grafting, tissue flaps, or implants.

Sources: grafting · tissue flaps · implants

For patients · Lumpectomy (Breast-Conserving Surgery)

Lumpectomy risks

Source: Lumpectomy (Breast-Conserving Surgery), National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

As with any surgery, lumpectomy has risks, including:

bleeding and pain at the site of surgery

infection

Sources: infection

fluid buildup near the site of surgery

lymphedema, if lymph nodes are removed

Sources: lymphedema

For patients

Mastectomy

Source: Mastectomy, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

In a mastectomy, the surgeon removes the whole breast that contains ductal carcinoma in situ (DCIS) or cancer. Your doctor may suggest a mastectomy if:

Sources: ductal carcinoma in situ

you have inflammatory breast cancer

Sources: inflammatory breast cancer

your breast has more than one tumor

you received radiation therapy to the chest in the past

Sources: radiation therapy

the cancer or DCIS is large relative to the size of the breast

you had a lumpectomy (breast-conserving surgery) that did not remove all the cancer cells

Sources: lumpectomy

you are at a high risk of a second breast cancer because of a genetic mutation or strong family history

Sources: genetic mutation

If you have a mastectomy, you may not need radiation therapy, so your doctor may also suggest a mastectomy if you are not able to have radiation therapy because you are pregnant or can’t commit to daily treatments.

People who have a mastectomy may need chemotherapy, hormone therapy, or targeted therapy. Learn more about Breast Cancer Treatment.

Sources: chemotherapy · hormone therapy · targeted therapy · Breast Cancer Treatment

After a mastectomy, you may choose to stay flat, wear a prosthesis (breast-like form) in your bra, or have breast reconstruction surgery.

Sources: breast reconstruction

For patients · Mastectomy

Types of mastectomy

Source: Mastectomy, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Types of mastectomy

Total mastectomy (also called simple mastectomy). In this type of surgery, the surgeon removes your whole breast, including the nipple, areola, breast tissue, and skin. Sometimes, they also remove one or more of the lymph nodes under your arm in a procedure called sentinel lymph node biopsy.

Sources: areola · tissue · lymph nodes · sentinel lymph node biopsy

Modified radical mastectomy. This is the same as a total mastectomy, but the surgeon also removes lymph nodes under your arm (axillary lymph node dissection). Because cancer cells may spread to the lymph nodes, lymph node removal can help reduce the risk of the cancer coming back. But it is often used only for more advanced stages of breast cancer.

Sources: axillary lymph node dissection

Skin-sparing mastectomy. The surgeon removes the whole breast, as in a total mastectomy, but leaves the skin. A skin-sparing mastectomy leaves less scarring and makes for a more natural-looking reconstructed breast. But if the tumor is large or near the skin, this procedure may not be an option. Skin-sparing mastectomies require breast reconstruction right after surgery.

Nipple-sparing mastectomy. The surgeon removes the whole breast but leaves the skin, nipple, and areola. Nipple-sparing mastectomy may not be an option if the tumor is large or if cancer cells are found near the skin, nipple, or areola. It also may not be an option for people with larger breasts.

Radical mastectomy. This type of mastectomy was common in the past, but it is now rarely performed because it does not improve how long people live. It involves removing the chest wall muscles and all lymph nodes, as well as the whole breast, nipple, areola, and skin. A surgeon may still suggest a radical mastectomy if the cancer cells have spread to the chest wall muscles.

Sources: chest wall

For patients · Mastectomy

Single vs. double mastectomy

Source: Mastectomy, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Single vs. double mastectomy

In a single (unilateral) mastectomy, only the breast with cancer is removed. A double (bilateral) mastectomy involves the removal of both breasts.

Your doctor may suggest a double mastectomy if:

cancer is in both breasts

you have cancer in one breast but are at high risk of developing cancer in the other breast because of a genetic mutation or strong family history of breast cancer

If you do not have a genetic mutation or strong family history of breast cancer, you do not have an increased risk of developing a new cancer in the other breast. For you, research shows that having a double mastectomy instead of a single mastectomy does not help you live longer.

You may choose to have a double mastectomy, even if your doctor suggests a single mastectomy, if:

you want to reduce the risk of developing a new breast cancer in the healthy breast

you prefer not to have routine screening to check for cancer in the healthy breast

you want both breasts to be the same size

you are concerned about how your chest will look after a single mastectomy

Discuss insurance coverage and the risks and benefits of a double mastectomy with your doctor before making a decision.

For patients · Mastectomy

Mastectomy with breast reconstruction surgery

Source: Mastectomy, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Mastectomy with breast reconstruction surgery

You can have breast reconstruction at the same time as the mastectomy, or at any time after. Some types of mastectomies (skin- and nipple-sparing) require reconstruction at the same time. Breast reconstruction is done by a plastic surgeon with experience in this type of surgery. The surgeon uses an implant or tissue from another part of your body to create the breast mound after the breast has been removed. If your nipple is removed, the surgeon may also make the form of a nipple and add a tattoo that looks like the areola.

Sources: plastic surgeon

For more information about types of breast reconstruction, recovery times, and possible complications, visit Breast Reconstruction After Mastectomy.

Sources: Breast Reconstruction After Mastectomy

For patients · Mastectomy

Going flat after a mastectomy

Source: Mastectomy, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Going flat after a mastectomy

You may choose to not have breast reconstruction after a mastectomy. This is called “going flat.” If you decide against reconstruction, you have the option of wearing a breast prosthesis to create the breast form under your clothes. To make the chest flat and smooth after a mastectomy, the surgeon will perform an aesthetic flat closure.

Sources: aesthetic flat closure

For patients · Mastectomy

Recovering after a mastectomy

Source: Mastectomy, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Recovering after a mastectomy

Recovery after a mastectomy depends on the type of mastectomy you had and whether you had breast reconstruction. Most people begin returning to normal activities 4 weeks after surgery. But recovery could take longer for people who have breast reconstruction.

For patients · Mastectomy

Mastectomy risks

Source: Mastectomy, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Mastectomy risks

As with any surgery, a mastectomy has possible risks:

infection

pain or other discomfort that may or may not get better over time (postmastectomy pain syndrome and phantom breast syndrome)

arm and shoulder pain and stiffness

lymphedema in the arm, especially when many lymph nodes have been removed

Sources: lymphedema

Mastectomy with reconstruction has additional risks. Learn more at Breast Reconstruction After Mastectomy.

Sources: Breast Reconstruction After Mastectomy

For patients

Targeted Therapy for Breast Cancer

Source: Targeted Therapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Targeted therapy is a type of cancer treatment that targets proteins that control how cancer cells grow, divide, and spread. To learn what to expect when receiving targeted therapy, visit Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Targeted Therapy for Breast Cancer

Who gets targeted therapy for breast cancer?

Source: Targeted Therapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Who gets targeted therapy for breast cancer?

Many people with breast cancer get targeted therapy but not everyone. For example, targeted therapy may be an option for some people with:

HER2-positive breast cancer

Sources: HER2-positive

hormone receptor–positive breast cancer

Sources: hormone receptor–positive

triple-negative breast cancer

Sources: triple-negative breast cancer

breast cancer that has a BRCA1 or BRCA2 mutation

Once breast cancer is diagnosed, breast cancer cells are routinely tested for the presence of certain biomarkers or tumor features. These tests can help determine if you are likely to benefit from targeted cancer therapy. To learn more, visit Tests for Breast Cancer Biomarkers.

Sources: biomarkers · Tests for Breast Cancer Biomarkers

For patients · Targeted Therapy for Breast Cancer

When is targeted therapy for breast cancer given?

Source: Targeted Therapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

When is targeted therapy for breast cancer given?

Targeted therapy for breast cancer may be given at different times in your treatment. It might be started before or after surgery. It can also be given even if surgery is not recommended for you.

For patients · Targeted Therapy for Breast Cancer

Targeted therapy for HER2-positive breast cancer

Source: Targeted Therapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Targeted therapy for HER2-positive breast cancer

HER2 is a protein that helps control breast cell growth. Some breast cancers have too much HER2, which causes the breast cells to grow and divide faster than normal. This is called HER2-positive breast cancer.

Several targeted therapy drugs may be used alone or with other kinds of drugs for HER2-positive breast cancer:

lapatinib

Sources: lapatinib

margetuximab

Sources: margetuximab

neratinib

Sources: neratinib

pertuzumab

Sources: pertuzumab

pertuzumab, trastuzumab, and hyaluronidase-zzxf

Sources: pertuzumab, trastuzumab, and hyaluronidase-zzxf

tucatinib

Sources: tucatinib

trastuzumab

Sources: trastuzumab

trastuzumab and hyaluronidase-oysk

Sources: trastuzumab and hyaluronidase-oysk

trastuzumab deruxtecan

Sources: trastuzumab deruxtecan

Some of these targeted therapy drugs, such as trastuzumab and trastuzumab deruxtecan, may also be used for HER-low breast cancer. HER2-low breast cancers have a small amount of HER2 protein on their surface.

For patients · Targeted Therapy for Breast Cancer

Targeted therapy for hormone receptor–positive breast cancer

Source: Targeted Therapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Targeted therapy for hormone receptor–positive breast cancer

In hormone receptor–positive (HR positive) breast cancer, the breast cancer cells have estrogen or progesterone receptors, or both.

The following targeted therapy drugs may be used alone or with other treatments, particularly hormone therapy:

abemaciclib

Sources: abemaciclib

alpelisib

Sources: alpelisib

everolimus

Sources: everolimus

palbociclib

Sources: palbociclib

ribociclib

Sources: ribociclib

sacituzumab govitecan

Sources: sacituzumab govitecan

These drugs may be given with hormone therapy, such as an aromatase inhibitor (such as anastrozole, letrozole, or exemestane) or fulvestrant or letrozole, to treat hormone receptor–positive, HER2-negative breast cancer. Learn more about Hormone Therapy for Breast Cancer.

Sources: anastrozole · letrozole · exemestane · fulvestrant · letrozole · Hormone Therapy for Breast Cancer

For patients · Targeted Therapy for Breast Cancer

Targeted therapy for triple-negative breast cancer

Source: Targeted Therapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Targeted therapy for triple-negative breast cancer

Triple-negative breast cancer is estrogen receptor (ER) negative, progesterone receptor (PR) negative, and HER2 negative.

The targeted therapy drug sacituzumab govitecan may be used to treat triple-negative breast cancer.

Sources: sacituzumab govitecan

Learn more about Triple-Negative Breast Cancer Treatment.

Sources: Triple-Negative Breast Cancer Treatment

For patients · Targeted Therapy for Breast Cancer

Targeted therapy for BRCA-positive breast cancer

Source: Targeted Therapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Targeted therapy for BRCA-positive breast cancer

BRCA1 and BRCA2 are genes that produce proteins that help fix damaged DNA. Certain changes, called mutations or pathogenic variants, in these genes can disrupt DNA repair and cause cancer to develop.

The following targeted therapy drugs may be used to treat BRCA1- or BRCA2-positive breast cancer:

olaparib

Sources: olaparib

talazoparib

Sources: talazoparib

For patients · Targeted Therapy for Breast Cancer

Side effects of targeted therapy

Source: Targeted Therapy for Breast Cancer, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Side effects of targeted therapy

The most common side effects of targeted therapy are diarrhea and liver problems. Other side effects may include mouth sores and hair and nail changes. Learn more about the side effects of cancer treatment and steps you can take to manage or prevent them.

Sources: diarrhea · mouth sores · nail changes · side effects of cancer treatment

For patients

Triple-Negative Breast Cancer Treatment

Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Triple-negative breast cancer (also called TNBC) does not have targets that are typically used to treat other types of breast cancer, but treatment options are available. You and your cancer care team will work together to create a personalized treatment plan, which may include more than one type of treatment. Learn more about Triple-Negative Breast Cancer.

Sources: Triple-Negative Breast Cancer

For patients · Triple-Negative Breast Cancer Treatment

Treating stages I–III triple-negative breast cancer

Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Treating stages I–III triple-negative breast cancer

If the cancer is small enough to be removed by surgery, the first treatment for stages I–III (also called stages 1 through 3) TNBC will usually be lumpectomy or mastectomy.

Sources: lumpectomy · mastectomy

Lumpectomy removes the cancer and a small margin of healthy breast tissue around it but not the breast itself. Lumpectomy is sometimes called breast-conserving surgery.

Sources: margin

Mastectomy removes the whole breast that has cancer. Some of the lymph nodes under the arm may also be removed.

Sources: lymph nodes

Learn more about Breast Cancer Surgery.

Sources: Breast Cancer Surgery

For larger tumors, chemotherapy may be given before surgery to shrink the cancer enough to make surgery possible and lessen the amount of breast tissue that needs to be removed during surgery. Additional drugs, such as the immunotherapy drug pembrolizumab, may be given with chemotherapy. Receiving treatment before surgery, called neoadjuvant therapy, may also improve long-term outcomes.

Sources: chemotherapy · immunotherapy · pembrolizumab

Learn about local and systemic treatments and access in-depth information about each type of treatment.

After surgery for TNBC, other treatments may be given to destroy any remaining cancer cells. These include:

more chemotherapy

more of the immunotherapy drug pembrolizumab

the targeted therapy drug olaparib, for those with a BRCA1 or BRCA2 gene mutation and who received chemotherapy both before and after surgery

Sources: targeted therapy · olaparib

radiation therapy, if cancer was found in or near lymph nodes or the tumor margin

Sources: radiation therapy · margin

For patients · Triple-Negative Breast Cancer Treatment

Treating metastatic or stage IV (also called stage 4) triple-negative breast cancer

Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Treating metastatic or stage IV (also called stage 4) triple-negative breast cancer

In metastatic (stage IV or stage 4) TNBC, the cancer has spread beyond the breast and nearby lymph nodes to distant parts of the body. Treatment for stage IV TNBC is focused on managing the disease and improving quality of life. Treatment options may include:

chemotherapy, which is usually the first treatment

Sources: chemotherapy

targeted therapy, such as olaparib (for those with a BRCA1 or BRCA2 gene mutation) or sacituzumab govitecan

Sources: targeted therapy · olaparib · sacituzumab govitecan

immunotherapy with pembrolizumab

Sources: immunotherapy · pembrolizumab

surgery, such as a mastectomy, to improve symptoms caused by a painful breast tumor or skin lesions

radiation therapy with strontium-89 to relieve pain from cancer that has spread to bones throughout the body

Sources: radiation therapy · strontium-89

radiation to the bones, brain, spinal cord, breast, or chest wall, or areas causing pain or discomfort

Sources: chest wall

For patients · Triple-Negative Breast Cancer Treatment

Treatment for recurrent triple-negative breast cancer

Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Treatment for recurrent triple-negative breast cancer

Treatment for TNBC that has recurred (come back) in distant parts of the body may be similar to treatment for stage IV breast cancer. When the cancer recurs locally, such as in the breast or nearby lymph nodes, surgery and radiation therapy may be an option to remove or shrink the tumor.

Learn more about treatments for breast cancer and breast cancer recurrence.

Sources: treatments for breast cancer · breast cancer recurrence

For patients · Triple-Negative Breast Cancer Treatment

Clinical trials

Source: Triple-Negative Breast Cancer Treatment, National Cancer Institute.

Source updated: Not stated in this source. Captured 2026-09-09.

Clinical trials

Connect with a cancer information specialist at 1-800-4-CANCER, through live chat, or by email.

Joining a clinical trial may be an option. There are different types of clinical trials for people with breast cancer. For example, a treatment trial tests new treatments or new ways of using existing treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials that are accepting participants. This search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. You can also review a list of NCI-supported Breast Cancer Clinical Trials. Clinical trials supported by other organizations can be found at ClinicalTrials.gov.

Sources: clinical trial search · Breast Cancer Clinical Trials · ClinicalTrials.gov

Learn more about clinical trials at Cancer Clinical Trial Information for Patients and Caregivers.

Sources: Cancer Clinical Trial Information for Patients and Caregivers

Studies

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

NCT00002707 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Lymph Node Radiation Therapy in Patients With Stage I, Stage II, or Stage III Breast Cancer That Has Been Surgically Removed

NCT00002851 · UNKNOWN · phase3

Breast Cancer

ClinicalTrials.gov record

Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer

NCT00003016 · UNKNOWN · phase3

Breast Cancer

ClinicalTrials.gov record

Combination Chemotherapy in Treating Patients With Breast Cancer

NCT00003088 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Letrozole After Tamoxifen in Treating Women With Breast Cancer

NCT00003140 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer

NCT00003418 · UNKNOWN · phase3

Breast Cancer

ClinicalTrials.gov record

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

NCT00003830 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer

NCT00003855 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Radiation Therapy With or Without Optional Tamoxifen in Treating Women With Ductal Carcinoma in Situ

NCT00003857 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

NCT00004067 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes

NCT00004125 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Letrozole or Tamoxifen in Treating Postmenopausal Women With Breast Cancer

NCT00004205 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer

NCT00005957 · COMPLETED · na

Breast Cancer

ClinicalTrials.gov record

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

NCT00005970 · COMPLETED · phase3

Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast...

ClinicalTrials.gov record

Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer

NCT00014612 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Exemestane in Treating Postmenopausal Women With Resected Stage I, Stage II, or Stage IIIA Breast Cancer Who Have Completed 5 Years of Tamoxifen

NCT00016432 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

NCT00021255 · COMPLETED · phase3

Breast Neoplasms

ClinicalTrials.gov record

Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer

NCT00045032 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Docetaxel and Trastuzumab With or Without Carboplatin in Treating Women With HER2-Positive Breast Cancer

NCT00047255 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

The Evaluation of the Efficacy and Tolerability of FASLODEX (Fulvestrant) and AROMASIN (Exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

NCT00065325 · COMPLETED · phase3

Locally Advanced Breast Cancer, Metastatic Breast Cancer

ClinicalTrials.gov record

Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer

NCT00066573 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066690 · COMPLETED · phase3

Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast...

ClinicalTrials.gov record

Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

NCT00066703 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer; Chemotherapy as Adjuvant for LOcally Recurrent Breast Cancer

NCT00074152 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

NCT00075764 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Capecitabine (XELODA) With Or Without Lapatinib (GW572016) For Women With Refractory Advanced or Metastatic Breast Cancer

NCT00078572 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer

NCT00078832 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy.

NCT00099437 · ACTIVE NOT RECRUITING · phase3

Breast Cancer

ClinicalTrials.gov record

Radiation Therapy (WBI Versus PBI) in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer

NCT00103181 · COMPLETED · na

Breast Cancer

ClinicalTrials.gov record

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer

NCT00248170 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy

NCT00256698 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

RAPID: Randomized Trial of Accelerated Partial Breast Irradiation

NCT00282035 · COMPLETED · na

Breast Cancer

ClinicalTrials.gov record

Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid

NCT00295646 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer

NCT00301457 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)

NCT00310180 · ACTIVE NOT RECRUITING · phase3

Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast...

ClinicalTrials.gov record

A Study Comparing Denosumab vs. Zoledronic Acid for the Treatment of Bone Metastases in Breast Cancer Subjects.

NCT00321464 · COMPLETED · phase3

Bone Metastases

ClinicalTrials.gov record

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer

NCT00321620 · COMPLETED · phase3

Bone Metastases

ClinicalTrials.gov record

Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma.

NCT00330759 · COMPLETED · phase3

Bone Metastases

ClinicalTrials.gov record

Trastuzumab for 6 Months or 1 Year in Treating Women With Nonmetastatic Breast Cancer That Can Be Removed By Surgery

NCT00381901 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer

NCT00382070 · UNKNOWN · phase3

Breast Cancer

ClinicalTrials.gov record

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

NCT00433420 · ACTIVE NOT RECRUITING · phase3

Breast Cancer

ClinicalTrials.gov record

Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes

NCT00433589 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

NCT00513292 · COMPLETED · phase3

HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer

ClinicalTrials.gov record

Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery

NCT00541086 · UNKNOWN · phase3

Breast Cancer

ClinicalTrials.gov record

Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer

NCT00542451 · COMPLETED · phase2

Breast Cancer, Carcinoma of the Breast

ClinicalTrials.gov record

A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.

NCT00545688 · COMPLETED · phase2

Breast Cancer

ClinicalTrials.gov record

Letrozole in Preventing Cancer in Postmenopausal Women Who Have Received 4-6 Years of Hormone Therapy for Hormone Receptor-Positive, Lymph Node-Positive, Early-Stage Breast Cancer

NCT00553410 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy

NCT00556374 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer

NCT00567190 · COMPLETED · phase3

Metastatic Breast Cancer

ClinicalTrials.gov record

F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer

NCT00602043 · COMPLETED · phase2

Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast...

ClinicalTrials.gov record

Trastuzumab in Treating Women With HER2-Positive Early Breast Cancer

NCT00712140 · UNKNOWN · phase3

Breast Cancer

ClinicalTrials.gov record

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer

NCT00829166 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

NCT00861705 · COMPLETED · phase2

Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma

ClinicalTrials.gov record

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole

NCT00863655 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

NCT00869206 · COMPLETED · phase3

Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary...

ClinicalTrials.gov record

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

NCT00878709 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women

NCT00912548 · UNKNOWN · phase3

Breast Cancer

ClinicalTrials.gov record

SWOG-8814 Tamoxifen With or Without Combination Chemotherapy in Postmenopausal Women Who Have Undergone Surgery for Breast Cancer

NCT00929591 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

NCT00950300 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer

NCT00976989 · COMPLETED · phase2

Breast Cancer

ClinicalTrials.gov record

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

NCT01007942 · COMPLETED · phase3

HER2/Neu Over-expressing Locally Advanced Breast Cancer, Metastatic Breast Cancer

ClinicalTrials.gov record

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

NCT01049425 · COMPLETED · phase3

Primary Breast Cancer, Her2 Non-overexpressing

ClinicalTrials.gov record

Letrozole in Treating Breast Cancer in Postmenopausal Women With Stage I, II, or III Breast Cancer Previously Treated With Tamoxifen (GIM4)

NCT01064635 · UNKNOWN · phase3

Breast Cancer

ClinicalTrials.gov record

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

NCT01077154 · TERMINATED · phase3

Breast Cancer

ClinicalTrials.gov record

Efficacy of Capecitabine Metronomic Chemotherapy to Triple-negative Breast Cancer

NCT01112826 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

NCT01120184 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Adjuvant Platinum and Taxane in Triple-negative Breast Cancer (PATTERN)

NCT01216111 · COMPLETED · phase3

Triple Negative Breast Cancer

ClinicalTrials.gov record

Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer

NCT01242800 · COMPLETED · na

Breast Cancer, Stage IV Breast Cancer

ClinicalTrials.gov record

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

NCT01272037 · ACTIVE NOT RECRUITING · phase3

Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma, Synchronous Bilateral Breast Carcinoma

ClinicalTrials.gov record

Tamoxifen-RAD001 Versus Tamoxifen Alone in Patients With Anti-aromatase Resistant Breast Metastatic Cancer

NCT01298713 · COMPLETED · phase2

Breast Neoplasms, mTor Protein

ClinicalTrials.gov record

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

NCT01358877 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Participant Preference of Subcutaneous (SC) Versus Intravenous (IV) Herceptin (Trastuzumab) in Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

NCT01401166 · COMPLETED · phase2

Breast Neoplasms

ClinicalTrials.gov record

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy

NCT01419197 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

NCT01426880 · COMPLETED · phase2, phase3

Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast...

ClinicalTrials.gov record

A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

NCT01566721 · COMPLETED · phase3

Breast Neoplasms

ClinicalTrials.gov record

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)

NCT01583426 · COMPLETED · phase3

Tubular Breast Cancer Stage II, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, Tubular Breast Cancer Stage III, HER-2 Positive Breast...

ClinicalTrials.gov record

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

NCT01602380 · COMPLETED · phase3

Hormone Receptor Positive Breast Cancer

ClinicalTrials.gov record

A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

NCT01740427 · COMPLETED · phase3

Breast Neoplasms

ClinicalTrials.gov record

A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE)

NCT01772472 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI

NCT01797120 · COMPLETED · phase2

Metastatic Breast Cancer

ClinicalTrials.gov record

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting

NCT01808573 · COMPLETED · phase3

HER2+ Metastatic Breast Cancer (MBC)

ClinicalTrials.gov record

Neoadjuvant Chemotherapy With Nab-paclitaxel in Women With HER2-negative High-risk Breast Cancer

NCT01822314 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

NCT01853748 · COMPLETED · phase2

Breast Cancer

ClinicalTrials.gov record

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

NCT01942135 · COMPLETED · phase3

Metastatic Breast Cancer

ClinicalTrials.gov record

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

NCT01945775 · COMPLETED · phase3

Breast Neoplasms, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation

ClinicalTrials.gov record

Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer

NCT01958021 · COMPLETED · phase3

Advanced, Metastatic Breast Cancer

ClinicalTrials.gov record

Diagnostic Accuracy and Safety Study of FES PET/CT in Assessment of ER Status of Recurrent or Metastatic Breast Cancer

NCT01986569 · COMPLETED · phase3

Recurrent Breast Cancer, Stage IV Breast Cancer

ClinicalTrials.gov record

Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2

NCT01996267 · ACTIVE NOT RECRUITING · phase3

Breast Cancer, HER2 Positive

ClinicalTrials.gov record

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.

NCT02000622 · COMPLETED · phase3

Breast Cancer Metastatic, BRCA 1 Gene Mutation, BRCA 2 Gene Mutation

ClinicalTrials.gov record

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823 · ACTIVE NOT RECRUITING · phase3

Breast Cancer

ClinicalTrials.gov record

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

NCT02069093 · COMPLETED · phase2

Advanced Breast Cancer

ClinicalTrials.gov record

A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

NCT02102490 · COMPLETED · phase2

Metastatic Breast Cancer

ClinicalTrials.gov record

Accelerated Partial Breast Irradiation Using Intensity Modulated Radiotherapy Versus Whole Breast Irradiation

NCT02104895 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

NCT02107703 · ACTIVE NOT RECRUITING · phase3

Breast Neoplasms

ClinicalTrials.gov record

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

NCT02132949 · COMPLETED · phase2

Breast Cancer

ClinicalTrials.gov record

Sentinel Node Vs Observation After Axillary Ultra-souND

NCT02167490 · ACTIVE NOT RECRUITING · na

Early Stage Breast Carcinoma

ClinicalTrials.gov record

Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial

NCT02181101 · COMPLETED · phase3

Breast Neoplasms

ClinicalTrials.gov record

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

NCT02246621 · ACTIVE NOT RECRUITING · phase3

Breast Cancer

ClinicalTrials.gov record

Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer

NCT02278120 · COMPLETED · phase3

Advanced Metastatic Breast Cancer

ClinicalTrials.gov record

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With Early-Stage HER2+ Breast Cancer Treated With Neratinib and Loperamide

NCT02400476 · COMPLETED · phase2

Early Stage HER2+ Breast Cancer

ClinicalTrials.gov record

Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.

NCT02422615 · COMPLETED · phase3

Advanced Breast Cancer

ClinicalTrials.gov record

A Study of Atezolizumab in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Participants With Previously Untreated Metastatic Triple-Negative Breast Cancer (IMpassion130)

NCT02425891 · COMPLETED · phase3

Triple Negative Breast Cancer

ClinicalTrials.gov record

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.

NCT02437318 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

NCT02445391 · ACTIVE NOT RECRUITING · phase3

Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast...

ClinicalTrials.gov record

Comparison of Axillary Sentinel Lymph Node Biopsy Versus no Axillary Surgery

NCT02466737 · ACTIVE NOT RECRUITING · na

Breast Cancer

ClinicalTrials.gov record

Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

NCT02492711 · COMPLETED · phase3

HER-2 Positive Breast Cancer, Metastatic Neoplasm

ClinicalTrials.gov record

Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)

NCT02555657 · COMPLETED · phase3

Metastatic Triple Negative Breast Cancer

ClinicalTrials.gov record

Trial of Sacituzumab Govitecan in Participants With Refractory/Relapsed Metastatic Triple-Negative Breast Cancer (TNBC)

NCT02574455 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer

NCT02614794 · COMPLETED · phase2

HER2 Positive Breast Cancer

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

NCT02628067 · ACTIVE NOT RECRUITING · phase2

Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer, Cholangiocarcinoma, Bile Duct Cancer, Neuroendocrine Tumor, Carcinoid Tumor, Endometrial Carcinoma, Endometrial...

ClinicalTrials.gov record

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

NCT02643420 · COMPLETED · phase3

Neutropenia, Breast Cancer

ClinicalTrials.gov record

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

NCT02693535 · RECRUITING · phase2

Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355)

NCT02819518 · COMPLETED · phase3

Triple Negative Breast Cancer (TNBC)

ClinicalTrials.gov record

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT02872103 · COMPLETED · phase3

Breast Cancer, Neutropenia

ClinicalTrials.gov record

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer

NCT02947685 · ACTIVE NOT RECRUITING · phase3

HER-2 Positive Breast Cancer, Estrogen Receptor Positive Breast Cancer

ClinicalTrials.gov record

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

NCT02953340 · COMPLETED · phase3

Neutropenia, Breast Cancer

ClinicalTrials.gov record

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02954874 · ACTIVE NOT RECRUITING · phase3

Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative...

ClinicalTrials.gov record

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

NCT03036488 · COMPLETED · phase3

Triple Negative Breast Neoplasms

ClinicalTrials.gov record

A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC)

NCT03125902 · COMPLETED · phase3

Triple-Negative Breast Cancer

ClinicalTrials.gov record

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

NCT03155997 · ACTIVE NOT RECRUITING · phase3

Breast Cancer

ClinicalTrials.gov record

A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1)

NCT03248492 · TERMINATED · phase2

Breast Cancer

ClinicalTrials.gov record

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

NCT03252431 · COMPLETED · phase3

Breast Cancer, Neutropenia

ClinicalTrials.gov record

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

NCT03493854 · COMPLETED · phase3

Early Breast Cancer

ClinicalTrials.gov record

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

NCT03498716 · TERMINATED · phase3

Triple Negative Breast Cancer

ClinicalTrials.gov record

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

NCT03523585 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

NCT03529110 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer

NCT03674112 · COMPLETED · phase2

HER2-Positive Early Breast Cancer

ClinicalTrials.gov record

Investigation of Novel Surgical Imaging for Tumor Excision

NCT03686215 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer

NCT03701334 · ACTIVE NOT RECRUITING · phase3

Early Breast Cancer

ClinicalTrials.gov record

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

NCT03734029 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer

NCT03778931 · COMPLETED · phase3

Breast Cancer

ClinicalTrials.gov record

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Participants With HR+/HER2- Metastatic Breast Cancer

NCT03901339 · COMPLETED · phase3

Metastatic Breast Cancer

ClinicalTrials.gov record

A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Participants With PIK3CA-Mutant, Hormone Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer

NCT04191499 · ACTIVE NOT RECRUITING · phase2, phase3

Breast Cancer

ClinicalTrials.gov record

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

NCT04300790 · COMPLETED · phase2

Breast Cancer

ClinicalTrials.gov record

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496 · ACTIVE NOT RECRUITING · phase3

Locally Advanced (Inoperable) or Metastatic Breast Cancer

ClinicalTrials.gov record

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425 · ACTIVE NOT RECRUITING · phase3

Advanced or Metastatic Breast Cancer

ClinicalTrials.gov record

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

NCT04622319 · ACTIVE NOT RECRUITING · phase3

HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer

ClinicalTrials.gov record

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715 · ACTIVE NOT RECRUITING · phase3

Breast Cancer; HER2-positive; Metastatic

ClinicalTrials.gov record

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934 · ACTIVE NOT RECRUITING · phase3

ER-Positive HER2-Negative Breast Cancer

ClinicalTrials.gov record

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

NCT04975308 · ACTIVE NOT RECRUITING · phase3

Breast Neoplasms, Neoplasm Metastasis

ClinicalTrials.gov record

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866 · ACTIVE NOT RECRUITING · phase3

Breast Cancer

ClinicalTrials.gov record

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251 · ACTIVE NOT RECRUITING · phase3

Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer

ClinicalTrials.gov record

A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

NCT05132582 · ACTIVE NOT RECRUITING · phase3

HER2 Positive Breast Cancer

ClinicalTrials.gov record

Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

NCT05169567 · ACTIVE NOT RECRUITING · phase3

Breast Neoplasm, Neoplasm Metastasis

ClinicalTrials.gov record

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512 · ACTIVE NOT RECRUITING · phase3

Breast Cancer

ClinicalTrials.gov record

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382286 · ACTIVE NOT RECRUITING · phase3

Triple Negative Breast Cancer, PD-L1 Positive

ClinicalTrials.gov record

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer

NCT05382299 · ACTIVE NOT RECRUITING · phase3

Triple Negative Breast Cancer, PD-L1 Negative

ClinicalTrials.gov record

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)

NCT05501886 · ACTIVE NOT RECRUITING · phase3

Breast Cancer

ClinicalTrials.gov record

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

NCT05654623 · ACTIVE NOT RECRUITING · phase3

Advanced Breast Cancer

ClinicalTrials.gov record

Overcoming Therapy Resistance in ER+ Breast Cancer Patients: a Translational Project (OVERTuRE)

NCT06129786 · UNKNOWN · Phase not reported

Breast Cancer

ClinicalTrials.gov record

Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates

NCT00104650 · COMPLETED · phase2

Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or...

ClinicalTrials.gov record

Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer

NCT00343382 · COMPLETED · phase3

Breast Cancer, Vaginal Dryness

ClinicalTrials.gov record

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

NCT00496860 · COMPLETED · phase1

Progressive Metastatic Malignancies

ClinicalTrials.gov record

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

NCT00587964 · COMPLETED · phase2

Brain Metastasis, Bladder Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, HEENT Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma,...

ClinicalTrials.gov record

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients

NCT00698035 · COMPLETED · phase2

Sexual Dysfunction, Physiological

ClinicalTrials.gov record

Open Label Extension to SRE Studies in United Kingdom and Czech Republic Only

NCT00950911 · COMPLETED · phase3

Bone Metastases in Men With Hormone-Refractory Prostate Cancer, Bone Metastases in Subjects With Advanced Breast Cancer, Bone Metastases in Subjects With Advanced Cancer or...

ClinicalTrials.gov record

Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors

NCT00981305 · COMPLETED · phase3

Sexual Dysfunction, Breast Cancer Survivors

ClinicalTrials.gov record

Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen

NCT00984399 · COMPLETED · na

Atrophic Vaginitis, Breast Cancer

ClinicalTrials.gov record

Cancer in Patients With Gabapentin (GPRD)

NCT01236053 · COMPLETED · Phase not reported

Pain, Neuropathic, Epilepsy, Renal Pelvis Cancer, Pancreatic Cancer, Breast Cancer, Nervous System Cancer, Chronic Pancreatitis, Stomach Cancer, Renal Cell Carcinoma, Diabetes,...

ClinicalTrials.gov record

Efficacy of Gamma Camera Used Intraoperatively for ID of Sentinel Lymph Nodes w/ Lymphoscintigraphy

NCT01314963 · COMPLETED · na

Multiple Myeloma, Breast Cancer

ClinicalTrials.gov record

Clinical Study of Vaginal Lactobacilli and Estriol (Gynoflor®) for Atrophic Vaginitis in Breast Cancer Patients

NCT01370551 · COMPLETED · phase1

Atrophic Vaginitis

ClinicalTrials.gov record

Prasterone (Dehydroepiandrosterone) in Treating Postmenopausal Cancer Survivors With Vaginal Symptoms

NCT01376349 · COMPLETED · phase3

Breast Cancer, Gynecologic Cancer

ClinicalTrials.gov record

Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy

NCT01422408 · COMPLETED · phase2

Breast Carcinoma

ClinicalTrials.gov record

Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients

NCT01434342 · COMPLETED · early phase1

Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer

ClinicalTrials.gov record

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

NCT01459653 · COMPLETED · Phase not reported

Febrile Neutropenia, Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Prostate Cancer, Multiple Myeloma, Bladder Cancer, B-cell Lymphoma

ClinicalTrials.gov record

Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking

NCT01535040 · COMPLETED · phase2

Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Tobacco Use Disorder

ClinicalTrials.gov record

Therapy to Prevent Sexual Pain in Breast Cancer Survivors

NCT01539317 · COMPLETED · phase3

Vulvodynia, Dyspareunia, Breast Cancer, Menopause

ClinicalTrials.gov record

Mithramycin for Lung, Esophagus, and Other Chest Cancers

NCT01624090 · TERMINATED · phase2

Lung Cancer, Esophageal Cancer, Mesothelioma, Gastrointestinal Neoplasms, Breast Cancer

ClinicalTrials.gov record

Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: The Effects of Vaginal Testosterone Therapy

NCT01697345 · COMPLETED · early phase1

Breast Cancer, Vaginal Dryness, Dyspareunia, Sexual Health Quality of Life

ClinicalTrials.gov record

Estradiol Levels in Patients Treated With Estring

NCT01923298 · COMPLETED · phase2

Estrogen Levels Among Breast Cancer Patients

ClinicalTrials.gov record

Reproductive Health Survivorship Care Plan Pilot

NCT02176083 · COMPLETED · na

Breast Cancer, Hot Flashes, Vaginal Dryness, Estrogen Deprivation Symptoms

ClinicalTrials.gov record

LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)

NCT02187783 · COMPLETED · phase2

Tumors With CDK4/6 Pathway Activation

ClinicalTrials.gov record

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

NCT02393248 · TERMINATED · phase1, phase2

Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer, Endometrial Cancer, Multiple Myeloma, Myeloproliferative Neoplasms, Breast Cancer, Cholangiocarcinoma, UC, MPN

ClinicalTrials.gov record

A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

NCT02413008 · COMPLETED · phase2

Vaginal Atrophy

ClinicalTrials.gov record

Reproductive Health Survivorship Care Plan

NCT02667626 · COMPLETED · na

Breast Cancer, Hot Flashes, Sexual Dysfunction, Fertility, Contraception

ClinicalTrials.gov record

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NCT03180294 · COMPLETED · phase2

Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma

ClinicalTrials.gov record

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

NCT03300843 · TERMINATED · phase2

Melanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer

ClinicalTrials.gov record

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

NCT03797326 · COMPLETED · phase2

Advanced Solid Tumors, Triple Negative Breast Cancer, Ovarian Cancer, Gastric Cancer, Colorectal Cancer, Glioblastoma, Biliary Tract Cancers, Pancreatic Cancer

ClinicalTrials.gov record

PROactive Evaluation of Function to Avoid CardioToxicity

NCT03862131 · TERMINATED · phase2

Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer

ClinicalTrials.gov record

Vaginal Dehydroepiandrosterone (DHEA) in Postmenopausal Breast Cancer Survivors on Aromatase Inhibitors

NCT04493333 · TERMINATED · phase2

Vaginal Atrophy, Postmenopausal Symptoms, Breast Cancer Female, Long-term Survivors

ClinicalTrials.gov record

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

NCT05185947 · COMPLETED · phase2

Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms, Ovarian Cancer, Ovarian Neoplasms, Colorectal Cancer, Colorectal Neoplasms,...

ClinicalTrials.gov record

Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor

NCT06048367 · COMPLETED · phase1

Advanced Solid Tumor, Lung Cancer, Pancreas Cancer, Breast Cancer, Thyroid Cancer, Colorectal Cancer, Cervical Cancer, Ovarian Cancer, Vulva Cancer

ClinicalTrials.gov record

Disease and treatment settings

ABRAXANE: metastatic breast cancer (adjuvant) after prior therapy

Disease and treatment setting

1.1 Metastatic Breast Cancer ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy.

advanced Breast Cancer

Disease and treatment setting

Treatment of Advanced Breast Cancer During Pregnancy

Afinitor: advanced breast cancer with HER2 negative after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment...

Afinitor: advanced breast cancer with HER2 Negative, HER2 negative after prior therapy

Disease and treatment setting

1.1 Hormone Receptor-Positive, HER2-Negative Breast Cancer AFINITOR ® is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, after...

ARIMIDEX: advanced breast cancer (second-line) after prior therapy

Disease and treatment setting

1.3 Second-Line Treatment ARIMIDEX is indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy.

Arimidex: breast cancer (adjuvant)

Disease and treatment setting

Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer

ARIMIDEX: metastatic breast cancer (first-line)

Disease and treatment setting

1.2 First-Line Treatment ARIMIDEX is indicated for the first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer.

Aromasin: advanced breast cancer after prior therapy

Disease and treatment setting

1.2 Advanced Breast Cancer in Postmenopausal Women AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].

Aromasin: breast cancer (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Treatment of Postmenopausal Women AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched...

Avastin: metastatic breast cancer with HER2 negative

Disease and treatment setting

In combination with paclitaxel for patients who have not received chemotherapy for metastatic HER2 negative breast cancer

AVGEMSI: metastatic breast cancer (first-line) after prior therapy

Disease and treatment setting

1.2 Breast Cancer AVGEMSI in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless anthracyclines...

BEIZRAY: breast cancer (adjuvant)

Disease and treatment setting

BEIZRAY in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

BEIZRAY: metastatic breast cancer after prior therapy

Disease and treatment setting

1.1 Breast Cancer BEIZRAY is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.

Breast Cancer

Disease and treatment setting

Breast Cancer

CLIGAVYX: advanced breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration

Disease and treatment setting

CLIGAVYX is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated...

CLIGAVYX: advanced breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, HR positive after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously...

CLIGAVYX: metastatic breast cancer with HR positive, HER2 negative after prior therapy

Disease and treatment setting

( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.

CLIGAVYX: metastatic breast cancer with HR positive, HER2 negative after prior therapy

Disease and treatment setting

( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

DATROWAY: unresectable metastatic breast cancer with HR Positive, HER2 Negative, HR stated without a specific alteration, HER2 stated without a specific alteration after prior ther

Disease and treatment setting

1.3 Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2...

DATROWAY: unresectable metastatic breast cancer with PD-L1 stated without a specific alteration

Disease and treatment setting

1.2 Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC) DATROWAY is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1...

Docetaxel: breast cancer (adjuvant)

Disease and treatment setting

Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

Docetaxel: metastatic breast cancer after prior therapy

Disease and treatment setting

1.1 Breast Cancer Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.

DOCIVYX: breast cancer (adjuvant)

Disease and treatment setting

DOCIVYX in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

DOCIVYX: metastatic breast cancer after prior therapy

Disease and treatment setting

1.1 Breast Cancer DOCIVYX is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.

Doxorubicin Hydrochloride: breast cancer (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Breast Cancer Doxorubicin Hydrochloride Injection is indicated as a component of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer .

Ellence: breast cancer (adjuvant) after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] .

Ellence: breast cancer (adjuvant) after prior therapy

Disease and treatment setting

ELLENCE is an anthracycline topoisomerase inhibitor indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer ( 1 ).

Enhertu: breast cancer with HER2 positive (neoadjuvant) after prior therapy

Disease and treatment setting

as adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant trastuzumab (with or without pertuzumab) and taxane-based treatment.

Enhertu: breast cancer with HER2 Positive, HER2 positive (neoadjuvant)

Disease and treatment setting

1.1 HER2-Positive Early Breast Cancer ENHERTU followed by a taxane, trastuzumab, and pertuzumab (THP) is indicated for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer as...

Enhertu: breast cancer with HER2 stated without a specific alteration, HER2 Positive, HER2 positive (neoadjuvant)

Disease and treatment setting

1 INDICATIONS AND USAGE ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II...

Enhertu: unresectable metastatic breast cancer with HER2 Low, HER2 stated without a specific alteration, HR stated without a specific alteration, HER2 low

Disease and treatment setting

1.3 HER2-Low and HER2-Ultralow Metastatic Breast Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic Hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or...

Enhertu: unresectable metastatic breast cancer with HER2 Positive, HER2 positive (first-line)

Disease and treatment setting

( 1.1 ) HER2-Positive Metastatic Breast Cancer in combination with pertuzumab as first-line treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer, as determined by an FDA-authorized test.

Enhertu: unresectable metastatic breast cancer with HER2 positive, HER2 stated without a specific alteration (neoadjuvant) after prior therapy

Disease and treatment setting

ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting,...

Enhertu: unresectable metastatic breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy

Disease and treatment setting

Adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting

Etcamah: metastatic breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, ESR1 mutation

Disease and treatment setting

In combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or...

EXEMESTANE: advanced breast cancer after prior therapy

Disease and treatment setting

1.2 Advanced Breast Cancer in Postmenopausal Women EXEMESTANE is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy [see Clinical Studies (14.2) ].

EXEMESTANE: breast cancer (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Treatment of Postmenopausal Women EXEMESTANE is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched...

Fareston: metastatic breast cancer

Disease and treatment setting

FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors.

FASLODEX: metastatic breast cancer with HR positive, HER2 negative after prior therapy

Disease and treatment setting

• HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

FASLODEX: metastatic breast cancer with HR positive, HER2 negative after prior therapy

Disease and treatment setting

• HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.

Femara: advanced breast cancer after prior therapy

Disease and treatment setting

Femara is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy [see Clinical Studies (14.4, 14.5)].

Femara: breast cancer (adjuvant)

Disease and treatment setting

Extended adjuvant treatment of early breast cancer in postmenopausal women who received 5 years of adjuvant tamoxifen

Femara: breast cancer (adjuvant) after prior therapy

Disease and treatment setting

1.2 Extended Adjuvant Treatment of Early Breast Cancer Femara is indicated for the extended adjuvant treatment of early breast cancer in postmenopausal women, who have received 5 years of adjuvant tamoxifen therapy.

Femara: breast cancer with HR positive

Disease and treatment setting

Postmenopausal women with HR positive early breast cancer

Femara: metastatic breast cancer (first-line)

Disease and treatment setting

1.3 First and Second-Line Treatment of Advanced Breast Cancer Femara is indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer.

Fulvestrant: advanced breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in...

Fulvestrant: advanced breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, HR positive after prior therapy

Disease and treatment setting

( 1 ) Monotherapy Fulvestrant Injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated...

Fulvestrant: metastatic breast cancer with HR positive, HER2 negative after prior therapy

Disease and treatment setting

( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

Fulvestrant: metastatic breast cancer with HR positive, HER2 negative after prior therapy

Disease and treatment setting

( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy.

GEMCITABINE: metastatic breast cancer (first-line) after prior therapy

Disease and treatment setting

1.2 Breast Cancer Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy, unless...

Halaven: metastatic breast cancer

Disease and treatment setting

1 INDICATIONS AND USAGE HALAVEN is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.

Herceptin Hylecta: breast cancer with HER2 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE HERCEPTIN HYLECTA is a combination of trastuzumab, a HER2/neu receptor antagonist, and hyaluronidase, an endoglycosidase, indicated in adults for: The treatment of HER2-overexpressing breast cancer.

Herceptin Hylecta: breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Breast Cancer HERCEPTIN HYLECTA is indicated for adjuvant treatment of adults with HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast...

Herceptin Hylecta: metastatic breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.2 Metastatic Breast Cancer HERCEPTIN HYLECTA is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast...

Herceptin: breast cancer with HER2 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE Herceptin is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.

Herceptin: breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Breast Cancer Herceptin is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as...

Herceptin: metastatic breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.2 Metastatic Breast Cancer Herceptin is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer...

HERZUMA: breast cancer with HER2 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE HERZUMA is a HER2/neu receptor antagonist indicated in adults for: the treatment of HER2-overexpressing breast cancer.

HERZUMA: metastatic breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.2 Metastatic Breast Cancer HERZUMA is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in...

Ibrance: metastatic breast cancer with HER2 negative

Disease and treatment setting

In combination with letrozole for postmenopausal women with ER-positive, HER2-negative advanced breast cancer as initial endocrine-based therapy for metastatic disease

Ibrance: metastatic breast cancer with HER2 Negative, HR stated without a specific alteration, HER2 stated without a specific alteration

Disease and treatment setting

1.1 HER2-Negative Metastatic Breast Cancer IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in...

Ibrance: metastatic breast cancer with HER2 Positive, HR positive, HER2 positive (maintenance) after prior therapy

Disease and treatment setting

1.2 HER2-Positive Metastatic Breast Cancer IBRANCE is indicated in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with HR-positive, HER2-positive locally...

Ibrance: metastatic breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration after prior therapy

Disease and treatment setting

• for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: o an aromatase inhibitor as initial...

Ibrance: metastatic breast cancer with PIK3CA stated without a specific alteration, HR positive, HER2 negative (adjuvant) after prior therapy

Disease and treatment setting

• in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA‑authorized...

Inluriyo: metastatic breast cancer with HER2 negative, ESR1 stated without a specific alteration after prior therapy

Disease and treatment setting

INLURIYO TM is an estrogen receptor antagonist indicated for: treatment of adults with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine...

Inluriyo: metastatic breast cancer with HER2 stated without a specific alteration, ESR1 stated without a specific alteration after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE INLURIYO is indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1 )-mutated advanced or metastatic breast...

Itovebi: metastatic breast cancer with PIK3CA stated without a specific alteration, HR stated without a specific alteration, HER2 stated without a specific alteration (adjuvant) af

Disease and treatment setting

1 INDICATIONS AND USAGE ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor...

Itovebi: metastatic breast cancer with PIK3CA stated without a specific alteration, HR stated without a specific alteration, HER2 stated without a specific alteration (adjuvant) af

Disease and treatment setting

ITOVEBI is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2...

IXEMPRA: metastatic breast cancer

Disease and treatment setting

IXEMPRA is a microtubule inhibitor indicated for treatment: In combination with capecitabine for patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is...

IXEMPRA: metastatic breast cancer after prior therapy

Disease and treatment setting

As a single agent for patients with metastatic or locally advanced breast cancer after failure of an anthracycline, a taxane, and capecitabine.

KADCYLA: breast cancer with HER2 positive (neoadjuvant) after prior therapy

Disease and treatment setting

( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.

KADCYLA: breast cancer with HER2 positive (neoadjuvant) after prior therapy

Disease and treatment setting

1.2 Early Breast Cancer (EBC) KADCYLA, as a single agent, is indicated for the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab -based...

KADCYLA: metastatic breast cancer with HER2 positive

Disease and treatment setting

1.1 Metastatic Breast Cancer (MBC) KADCYLA ® , as a single agent, is indicated for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination.

KADCYLA: metastatic breast cancer with HER2 stated without a specific alteration, HER2 positive

Disease and treatment setting

1 INDICATIONS AND USAGE KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received...

Kanjinti: breast cancer with HER2 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE KANJINTI is a HER2/neu receptor antagonist indicated in adults for: the treatment of HER2-overexpressing breast cancer.

Kanjinti: breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Breast Cancer KANJINTI is indicated in adults for adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part...

Kanjinti: metastatic breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.2 Metastatic Breast Cancer KANJINTI is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer...

KEYTRUDA QLEX: breast cancer (neoadjuvant) after prior therapy

Disease and treatment setting

1.18 Triple-Negative Breast Cancer KEYTRUDA QLEX is indicated for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then...

KEYTRUDA: breast cancer (neoadjuvant) after prior therapy

Disease and treatment setting

1.20 Triple-Negative Breast Cancer KEYTRUDA is indicated for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as a...

KISQALI: breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration (adjuvant)

Disease and treatment setting

1.1 Early Breast Cancer KISQALI is indicated in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III...

KISQALI: metastatic breast cancer with HR positive, HER2 negative after prior therapy

Disease and treatment setting

( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or...

localized Breast Cancer

Disease and treatment setting

Treatment of Early/Localized/Operable Breast Cancer During Pregnancy

Lynparza: breast cancer with BRCA stated without a specific alteration, HER2 negative, HER2 stated without a specific alteration (neoadjuvant) after prior therapy

Disease and treatment setting

1.4 Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epidermal growth...

Lynparza: metastatic breast cancer with BRCA stated without a specific alteration, HER2 negative (neoadjuvant) after prior therapy

Disease and treatment setting

1.5 Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated...

MARGENZA: metastatic breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE MARGENZA is indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of...

MARGENZA: metastatic breast cancer with HER2 stated without a specific alteration, HER2 positive after prior therapy

Disease and treatment setting

MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one...

metastatic Breast Cancer

Disease and treatment setting

Treatment of Metastatic Breast Cancer

Nerlynx: breast cancer with HER2 positive (adjuvant)

Disease and treatment setting

1 INDICATIONS AND USAGE NERLYNX is a kinase inhibitor indicated: As a single agent, for the extended adjuvant treatment of adult patients with early-stage HER2-positive breast cancer, to follow adjuvant trastuzumab-based therapy.

Nerlynx: breast cancer with HER2 stated without a specific alteration (adjuvant)

Disease and treatment setting

1.1 Extended Adjuvant Treatment of Early-Stage Breast Cancer NERLYNX as a single agent is indicated for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2 (HER2)-positive breast...

Nerlynx: metastatic breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy

Disease and treatment setting

1.2 Advanced or Metastatic Breast Cancer NERLYNX in combination with capecitabine is indicated for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2...

Nerlynx: metastatic breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy

Disease and treatment setting

In combination with capecitabine, for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 based regimens in the metastatic setting.

OGIVRI: breast cancer with HER2 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE Ogivri is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.

OGIVRI: breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Breast Cancer Ogivri is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as part...

OGIVRI: metastatic breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.2 Metastatic Breast Cancer Ogivri is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer in...

Ontruzant: breast cancer with HER2 stated without a specific alteration

Disease and treatment setting

1 INDICATIONS AND USAGE Ontruzant is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer.

Ontruzant: breast cancer with HER2 stated without a specific alteration (adjuvant) after prior therapy

Disease and treatment setting

1.1 Adjuvant Breast Cancer Ontruzant is indicated in adults for adjuvant treatment of HER2 overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer as...

Ontruzant: metastatic breast cancer with HER2 stated without a specific alteration (first-line) after prior therapy

Disease and treatment setting

1.2 Metastatic Breast Cancer Ontruzant is indicated in adults: In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of HER2-overexpressing breast cancer...

ORSERDU: metastatic breast cancer with HER2 negative, ESR1 stated without a specific alteration after prior therapy

Disease and treatment setting

ORSERDU is an estrogen receptor antagonist indicated for: treatment of postmenopausal women or adult men, with ER-positive, HER2-negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with...

ORSERDU: metastatic breast cancer with HER2 stated without a specific alteration, ESR1 stated without a specific alteration after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic...

PACLITAXEL PROTEIN BOUND PARTICLES ALBUMIN BOUND: metastatic breast cancer (adjuvant) after prior therapy

Disease and treatment setting

1.1 Metastatic Breast Cancer Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound) is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within...

Paclitaxel: metastatic breast cancer (adjuvant) after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE Paclitaxel Protein-Bound Particles for Injectable Suspension (albumin-bound) is a microtubule inhibitor indicated for the treatment of: Metastatic breast cancer, after failure of combination chemotherapy for...

Perjeta: locally advanced breast cancer with HER2 positive (neoadjuvant)

Disease and treatment setting

In combination with trastuzumab and docetaxel for neoadjuvant treatment of HER2-positive locally advanced inflammatory or early-stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment...

PERJETA: metastatic breast cancer with HER2 positive, HER2 stated without a specific alteration

Disease and treatment setting

1.1 Metastatic Breast Cancer (MBC) PERJETA is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or...

PERJETA: metastatic breast cancer with HER2 stated without a specific alteration, HER2 positive

Disease and treatment setting

1 INDICATIONS AND USAGE PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior...

Phesgo: locally advanced breast cancer with HER2 positive (neoadjuvant)

Disease and treatment setting

1.1 Early Breast Cancer (EBC) PHESGO is indicated for use in combination with chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater...

Phesgo: locally advanced breast cancer with HER2 stated without a specific alteration, HER2 positive (neoadjuvant)

Disease and treatment setting

1 INDICATIONS AND USAGE PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of...

Phesgo: metastatic breast cancer with HER2 positive, HER2 stated without a specific alteration

Disease and treatment setting

1.2 Metastatic Breast Cancer (MBC) PHESGO is indicated for use in combination with docetaxel for the treatment of adult patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy...

PIQRAY: metastatic breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, PIK3CA stated without a specific alteration after prior th

Disease and treatment setting

1 INDICATIONS AND USAGE PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or...

recurrent Breast Cancer

Disease and treatment setting

Treatment of Locoregional Recurrent Breast Cancer

SOLTAMOX: breast cancer (adjuvant)

Disease and treatment setting

1.2 Adjuvant Treatment of Breast Cancer SOLTAMOX is indicated: for the adjuvant treatment of adult patients with early stage estrogen receptor-positive breast cancer to reduce the occurrence of contralateral breast cancer in adult...

SOLTAMOX: Carcinoma In Situ after prior therapy

Disease and treatment setting

1.3 Ductal Carcinoma in Situ In adult women with DCIS, following breast surgery and radiation, SOLTAMOX is indicated to reduce the risk of invasive breast cancer [see Boxed Warning and Clinical Studies (14.3) ] .

SOLTAMOX: metastatic breast cancer

Disease and treatment setting

1 INDICATIONS AND USAGE SOLTAMOX is an estrogen agonist/antagonist indicated: For treatment of adult patients with estrogen receptor-positive metastatic breast cancer ( 1.1 )

Stage 0 Breast Cancer

Disease and treatment setting

Treatment of stage 0 breast cancer (ductal carcinoma in situ)

Stage III Breast Cancer

Disease and treatment setting

Treating stage III (also called stage 3) inflammatory breast cancer

Stage IV Breast Cancer

Disease and treatment setting

Treatment of stage IV (metastatic) breast cancer

Talzenna: metastatic breast cancer with BRCA stated without a specific alteration, HER2 negative

Disease and treatment setting

• As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m) HER2-negative locally advanced or metastatic breast cancer.

Talzenna: metastatic breast cancer with BRCA stated without a specific alteration, HER2 negative, HER2 stated without a specific alteration

Disease and treatment setting

1.1 BRCA -mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer...

Taxotere: metastatic Breast Carcinoma (adjuvant)

Disease and treatment setting

Locally advanced or metastatic breast carcinoma that progressed during anthracycline-based therapy or relapsed during anthracycline-based adjuvant therapy

Tecentriq: unresectable metastatic breast cancer with PD-L1 stated without a specific alteration

Disease and treatment setting

In combination with paclitaxel protein-bound for unresectable locally advanced or metastatic triple-negative breast cancer whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering = 1% of the...

Trazimera: breast cancer with HER2 stated without a specific alteration (adjuvant)

Disease and treatment setting

1.1 Adjuvant Breast Cancer TRAZIMERA is indicated in adults for adjuvant treatment of HER2-overexpressing node positive or node negative (ER/PR negative or with one high risk feature [see Clinical Studies (14.1) ] ) breast cancer

Trazimera: metastatic breast cancer

Disease and treatment setting

1.2 Metastatic Breast Cancer TRAZIMERA is indicated in adults:

Trazimera: metastatic breast cancer with HER2 stated without a specific alteration (first-line)

Disease and treatment setting

• In combination with paclitaxel for first-line treatment of HER2-overexpressing metastatic breast cancer

TRODELVY: unresectable metastatic breast cancer with HR positive, HER2 negative, HR stated without a specific alteration, HER2 stated without a specific alteration after prior ther

Disease and treatment setting

1.2 Locally Advanced or Metastatic HR-positive, HER2-negative Breast Cancer TRODELVY is indicated for the treatment of adult patients with unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal...

TRODELVY: unresectable metastatic breast cancer with PD-L1 stated without a specific alteration (first-line)

Disease and treatment setting

1.1 Locally Advanced or Metastatic Triple-Negative Breast Cancer First Line TRODELVY as a single agent is indicated for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple negative breast...

TRUQAP: metastatic breast cancer with HR positive, HER2 negative, HR stated without a specific alteration, HER2 stated without a specific alteration, PIK3CA stated without a specif

Disease and treatment setting

1.1 HR-positive, HER2-negative locally advanced or metastatic breast cancer TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor...

TRUQAP: metastatic breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, PIK3CA stated without a specific alteration (adjuvant) aft

Disease and treatment setting

• in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more...

TUKYSA: unresectable metastatic breast cancer with HER2 positive, HER2 stated without a specific alteration after prior therapy

Disease and treatment setting

• in combination with trastuzumab and capecitabine for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior...

TYKERB: metastatic breast cancer

Disease and treatment setting

TYKERB in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer.

TYKERB: metastatic breast cancer with HER2 stated without a specific alteration

Disease and treatment setting

Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with TYKERB in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone...

TYKERB: metastatic breast cancer with HER2 stated without a specific alteration after prior therapy

Disease and treatment setting

1 INDICATIONS AND USAGE TYKERB ® is indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who...

Tykerb: metastatic breast cancer with HR positive, HER2 stated without a specific alteration

Disease and treatment setting

In combination with letrozole for post-menopausal women with HR-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated

VEPPANU: metastatic breast cancer with HER2 stated without a specific alteration, ESR1 stated without a specific alteration after prior therapy

Disease and treatment setting

VEPPANU is a heterobifunctional protein degrader indicated for the treatment of adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor-1 ( ESR1) -mutated advanced or...

Verzenio: breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration (adjuvant)

Disease and treatment setting

1 INDICATIONS AND USAGE VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human...

Verzenio: metastatic breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration

Disease and treatment setting

( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or...

Verzenio: metastatic breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration after prior therapy

Disease and treatment setting

in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following...

Verzenio: metastatic breast cancer with HR stated without a specific alteration, HER2 stated without a specific alteration, HR positive, HER2 negative after prior therapy

Disease and treatment setting

1.2 Advanced or Metastatic Breast Cancer VERZENIO (abemaciclib) is indicated: in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human...

Xeloda: metastatic breast cancer

Disease and treatment setting

Metastatic breast cancer resistant to paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and further anthracycline therapy is contraindicated

XELODA: metastatic breast cancer after prior therapy

Disease and treatment setting

1.2 Breast Cancer XELODA is indicated for the: treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. treatment of patients with...

ZOLADEX: advanced breast cancer

Disease and treatment setting

1.5 Advanced Breast Cancer ZOLADEX is indicated for use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women.

Drug labels

ARIMIDEX

Label date 2026-03-02

ARIMIDEX is an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1 ) • First-line treatment of postmenopausal women with hormone receptor-positive or...

DailyMed label

Aromasin

Label date 2025-12-24

AROMASIN is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for...

DailyMed label

BEIZRAY

Label date 2025-12-15

BEIZRAY is a microtubule inhibitor indicated for: Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable...

DailyMed label

Cardiolite

Label date 2022-12-06

1. INDICATIONS AND USAGE CARDIOLITE® is a myocardial perfusion agent indicated for: detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects) evaluating myocardial...

DailyMed label

CERIANNA

Label date 2026-01-12

CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. CERIANNA is a...

DailyMed label

CLIGAVYX

Label date 2026-06-24

Monotherapy CLIGAVYX is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine...

DailyMed label

Conjugated Estrogens

Label date 2026-02-27

Conjugated Estrogens Tablets are a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) •...

DailyMed label

DATROWAY

Label date 2026-05-27

DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer...

DailyMed label

Ellence

Label date 2026-07-24

ELLENCE is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer [see Clinical Studies (14.1) ] . ELLENCE is an anthracycline topoisomerase...

DailyMed label

Enhertu

Label date 2026-05-15

ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for: HER2-Positive Early Breast Cancer as neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as...

DailyMed label

Evista

Label date 2026-02-11

EVISTA ® is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. ( 1.2 ) Reduction...

DailyMed label

EXEMESTANE

Label date 2025-12-24

EXEMESTANE is an aromatase inhibitor indicated for: • adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to EXEMESTANE for...

DailyMed label

Fareston

Label date 2024-11-13

FARESTON® is an estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. FARESTON® is an estrogen agonist/antagonist indicated for the...

DailyMed label

FASLODEX

Label date 2020-09-25

Monotherapy FASLODEX is indicated for the treatment of: • Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine...

DailyMed label

Femara

Label date 2026-06-11

Femara is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have...

DailyMed label

Fulvestrant

Label date 2024-01-31

Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not...

DailyMed label